Protocol I5Q -MC-CGAG 
 
 
A Phase 3, Randomized, Double -Blind, Placebo-Controlled Study of LY2951742 in Patients with 
Episodic Migraine – the EVOLVE -1 Study 
 
 
 
[STUDY_ID_REMOVED]   
 
Approval Date: 23- Sep-2015 
I5Q -MC -CGAG  C l in ica l  P ro toco l  Page  1  
LY2951742  P ro toco l  I5Q -MC -CGAG  
A  Phase  3 ,  Random i zed ,  Doub le -B l ind ,  P lacebo -Con t ro l led  
S tudy  o f  LY2951742  in  Pa t ien ts  w i th  Ep isod ic  M ig ra ine  –   
the  EVOLVE -1  S tudy  
 
Con f iden t ia l  In fo rma t ion  
The  in fo rma t ion  con ta ined  in  th is  documen t  is con f iden t ia l  and  is  in tended  fo r  the  use  o f  
c l in i ca l  inve s t iga to r s .   I t  is  the  p rope r ty  o f E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies  and  shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rsons  no t  invo lved  in  the  c l in ica l  inves t iga t ion  o f  LY2951742 ,  un less  such  pe rsons  a re  bound  by  a  con f iden t ia l i ty  ag reemen t  w i th  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies .    
No te  to  Regu la to ry  Au tho r i t ies:  th is  documen t  may  con ta i n  p ro tec ted  pe rsona l  da ta  
and /o r  comme rc ia l ly  con f iden t ia l  in fo rma t ion  exemp t  f rom  pub l ic  d isc losu re .  E l i  L i l ly  and  Company  reques ts  consu l ta t ion  rega rd ing  re lea se / reda c t ion  p r io r  to  any  pub l ic  re lease .  In  
the  Un i ted  S ta tes ,  th is  documen t  is  sub jec t  to  F reedom  o f  In fo rma t ion  A c t  (FO IA )  
Exemp t ion  4  and  may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  w r i t ten  app rova l  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ie s .  
LY2951742  
S tudy  CGAG  is  a  Phase  3 ,  mu l t is i te ,  random ized ,  doub le -b l ind ,  p lacebo -con t ro l led ,  6 -
mon th  s tudy  to  compa re  the  e f f icacy  and  sa fe ty  o f  two  doses  o f  LY2951742  w i th  p lacebo  in  
p reven t ing  m ig ra ine  headaches  in  pa t ien ts  w i th  ep isod ic  m ig ra ine  (w i th  o r  w i thou t  au ra ) .  
E l i  L i l l y  and  Compan y  
Ind ianapo l i s ,  Ind iana  USA  46285  
P ro to co l  E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l l y  on  da te  p ro v ided  be low .  
 
 
App ro va l  Da te :  23 -Sep -2015  GMT 
I5Q-MC-CGAG Clinical Protocol Page 2
LY2951742Table of Contents
Section Page
1. Protocol  Synopsi s................................................................................................................ 8
2. Introduction ...................................................................................................................... 11
2.1. Backgro und.................................................................................................................. 11
2.2. Study  Rati onale ............................................................................................................ 11
3. Object ives and Endpo ints.................................................................................................. 13
4. Study  Design ..................................................................................................................... 19
4.1. Overview of Study  Design ........................................................................................... 19
4.2. End of Trial Definit ion.................................................................................................21
4.3. Scientific Rationale for Study  Design ........................................................................... 21
4.4. Justification for Dose ................................................................................................... 21
4.5. Benefit/Risk Assessment .............................................................................................. 21
5. Study  Popul ation............................................................................................................... 22
5.1. Inclusio n Cri teria.......................................................................................................... 22
5.2. Exclusio n Cri teria........................................................................................................ 23
5.3. Screen Failures ............................................................................................................. 26
5.4. Lifest yle and/or Dietary Requirements ......................................................................... 27
6. Treatment .......................................................................................................................... 28
6.1. Treatments Administered ............................................................................................. 28
6.1.1. Medical Devices ................................................................................................... 28
6.2. Method of Treatment Assignment ................................................................................ 28
6.2.1. Selection and Timing o f Doses ............................................................................. 28
6.3. Blinding ....................................................................................................................... 28
6.4. Packaging and Labelling .............................................................................................. 29
6.5. Preparati on/Handling/Storage ....................................................................................... 29
6.6. Dose Modificat ion........................................................................................................ 29
6.6.1. Speci al Treatm ent Consi derat ions........................................................................ 29
6.7. Treatment Compliance .................................................................................................30
6.8. Concomitant Therapy ................................................................................................... 30
6.9. Treatment after Study  Com pletion................................................................................ 30
6.9.1. Study  Extensio ns.................................................................................................. 30
6.9.2. Continued Access .................................................................................................30
7. Discontinuati on Cri teria .................................................................................................... 31
7.1. Discontinuati on from Study  Treatm ent......................................................................... 31
7.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 31
I5Q - MC- CGAG  C l in ica l  P ro toco l Page  3
LY2951742PPD7 . 1 . 2 . T empo r a ry  D i s c o n t i n u a t i o n  f r o m  S tudy T r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
7 . 1 . 3 . D is con t inu a t i on  o f  I n a d v e r t e n t l y  Enro l l ed  P a t i en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
7 . 1 . 4 . P e rma n e n t  D i s c o n t i n u a t i o n  f r om  t h e  S t u d y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
7 . 1 . 5 . P a t ie n t s  L o s t  t o  F o l l ow - U p. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
8 . S tudy A s s e s sm e n t s  and  P ro c edu r e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
8 .1 . E f f i c a c y  A s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
8 . 1 . 1 . P r im a r y  E f f i c a c y A s s e s sm en t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
8 . 1 . 2 . S e cond a ry E f f i c a cy  A s s e s sm en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
8 .1 .2 .1 . P a t ien t  G l ob a l  Im p r e s s i on  o f  S ev e r i ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
8 .1 .2 .2 . P a t ien t  G l ob a l  Im p r e s s i on  o f  Im p r o v em e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
8 . 1 . 3 . A p p r o p r i a t e n e s s  o f  A s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
8 .2 . A dv e r s e  Ev en t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
8 . 2 . 1 . S e r io u s  A d v e r s e  E v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
8 .2 .1 .1 . S u s p e c t e d  U n e x p e c t e d  S e r i o u s  A d v e r s e  R e a c ti o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
8 .2 .1 .2 . A dv e r s e  E v e n t  M o n i t o r i n g  w i t h  a  S y s t em a ti c  
Q u e s ti o n n a i r e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 5
8 . 2 . 2 . Comp l a in t  H and l ing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
8 .3 . T r e a tm e n t  o f  O v e r d o s e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 6
8 .4 . S a fe t y  A s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
8 . 4 . 1 . E l e c t r o c a r d i o g r am s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
8 . 4 . 2 . V it a l  S ign s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 6
8 . 4 . 3 . L abo r a to ry  T e s t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
8 . 4 . 4 . O th e r  T e s t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
8 . 4 . 5 . S a fe t y  Mon ito r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
8 .5 . P h a rm a c o k i n e ti c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
8 .6 . P h a rm a c o d y n am i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
8 .8 . B iom a rk e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
8 . 8 . 1 . S amp l e s  f o r  Imm u n o g e n i c i ty  R e s e a r ch . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 9
8 .9 . H e a l th  E conom i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
9 . S t a t is t i c a l  C o n s i d e r a t i o n s  a n d  D a t a  A n a l y s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
9 .1 . D e t e rm i n a ti o n  o f  S am p l e  S i z e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
9 .2 . G e n e r a l  S t a t i s ti c a l  C o n s i d e r a ti o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
9 .3 . T r e a tm e n t  G r o u p  C om p a r a b i l i ty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
9 . 3 . 1 . P a t ien t  D i spo s i t i on. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
9 . 3 . 2 . P a t ien t  Ch a r a c t e r i s t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
9 . 3 . 3 . Con com i t an t  Th e r apy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
9 .3 . 4 . T r e a tm e n t  C om p l i a n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
I5Q - MC- CGAG  C l in ica l  P ro toco l Page  4
LY2951742PPD9 . 3 . 5 . E l e c t r o n i c  P a ti e n t- r e p o r t e d  O u t c om e  D i a r y  C o m pl i a n c e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3
9 .4 . P r im a ry  and  S e cond a ry An a ly s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3
9 . 4 . 1 . P r im a r y  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 3
9 .4 .2 . K e y  S e c o n d a r y An a ly s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
9 . 4 . 3 . O th e r  S e cond a ry and  T e r t i a ry  E f f i c a cy  An a ly s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
9 .5 . S a fe t y  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
9 .5 .1 .1 . C a t e g o r i c a l  S a f e ty  V a r iab l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
9 .5 .1 .2 . A dv e r s e  Ev en t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
9 .5 .1 .3 . Su ic i d e - R e l a t e d  T h o u g h t s  a n d  B e h a v i o r s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
9 .5 .1 .4 . V it a l  S i g n s  a n d  W e i g h t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
9 .5 .1 .5 . E l e c t r o c a r d i o g r am  I n t e r v a l s  a n d  H e a r t  R a t e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
9 .5 .1 .6 . L abo r a to ry T e s t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
9 .7 . O t h e r  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
9 . 7 . 1 . H e a lth  E conom i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
9 . 7 . 2 . S u b g r o u p  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
9 .8 . I n t e r im  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 8
1 0 .Study  G o v e r n a n c e  C o n s i d e r a t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 9
10 .1 .R egu l a to ry and  E th i c a l  Con s id e r a t i o n s ,  I n c l u d i n g  t h e  I n f o rm e d  
C o n s e n t  P r o c e s s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 9
1 0 . 1 . 1 . In fo rm e d  C o n s e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 9
1 0 . 1 . 2 . E t h i c a l  R e v i ew. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 9
1 0 . 1 . 3 . R egu l a to ry C o n s i d e r a t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 9
1 0 . 1 . 4 . I n v e s t i g a t o r  I n f o rm a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
1 0 . 1 . 5 . P ro to co l S i gn a tu r e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
1 0 . 1 . 6 . F in a l  R epo r t  S ign a tu r e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
10 .2 .D a t a  Q u a l i ty  A s s u r a n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
1 0 . 2 . 1 . D a t a  C ap tu r e  Sy s t em. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1
10 .3 .S tudy and  S i t e  C l o su r e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 2
1 0 . 3 . 1 . D is con t inu a t i on  o f  S tudy  S i t e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2
1 0 . 3 . 2 . D is con t inu a t i on  o f  th e  S tudy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2
1 1 .R e f e r e n c e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3
I5Q-MC-CGAG Clinical Protocol Page 5
LY2951742List of Tables
Table Page
Table CGAG.1. Objectives and Endpo ints............................................................................... 13
Table CGAG.2. Migraine and Headache Endpo int Definit ions................................................ 17
Table CGAG.3. Definit ion of Subgroup Variables .................................................................. 48
I5Q-MC-CGAG Clinical Protocol Page 6
LY2951742List of Figures
Figure Page
Figure CGAG.1. Illustrati on of  study  design for Clinical Protocol I5Q -MC-CGAG. ................. 19
I5Q-MC-CGAG Clinical Protocol Page 7
LY2951742List of A ppendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 55
Appendix 2. Schedule of Act ivities.................................................................................... 56
Appendix 3. Clinical Laboratory  Tests ............................................................................... 61
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 63
I5Q-MC-CGAG Clinical Protocol Page 8
LY29517421.Protocol Synopsis
Title of Study:
A Phase 3, Randomized, Double -Blind, Placebo -Controlled Study of LY2951742 in Patients with Episodic Migraine
–the EVOLVE -1 Study .
Rationale: 
Study I5Q-MC -CGAG (CGAG ; EVOLVE -1) is intended to assess the efficacy and safety of two doses of
LY2951742 in the prevention of migraine headache com pared with placebo in patients suffering from episodic 
migraine.   Episodic migraine is defined as 4 to 14 migraine headache days (with o r without aura) per month.
I5Q-MC-CGAG Clinical Protocol Page 9
LY2951742Objectives/Endpoints:
Objectives Endpoints
Primary
To test the hypothesis that at least 1 dose of LY2951742 
(120 o r 240 mg/month )is superior to placebo in the 
prevention of migraine headache in patients with 
episodic migraine.The overall mean change from baseline in the number 
of monthly migraine headache days during the 6 -
month d ouble -blind treatment phase
Key Secondary Objectives
If LY2951742 (120 or 240 mg/month ) is statistically 
significantly  superior to placebo on the primary 
objective , the following key secondary objectives will be 
tested w ith adjustment for multiplicity (only  the key  
secondary objectives are listed below):The specific methodology (including testing order, 
relatio nship and type I error allocation and 
propagation) for the tests of the following key 
secondary endpoints will be specified in t he statistica l 
analy sis plan:  
To compare LY2951742 with placebo with respect 
to50% response rateThe proportion of patients with reduction from 
baseline ≥50% in monthly  migraine headache 
days during the 6- month double -blind treatment 
phase
To compare LY2951742 with placebo with respect 
to 75% response rateThe proportion of patients with reduction from 
baseline ≥75% in monthly migraine headache 
days during the 6- month double -blind treatment 
phase
To compare LY2951742 with placebo with respect 
to 100% response rateThe proportion of patients with a 100% reduction 
from baseline in monthly migraine headache 
days during the 6- month double -blind treatment 
phase
To compare LY2951742 with placebo with respect 
tochange in function ingMean change from baseline in the Role Function -
Restrictive domain score of the Migraine -
Specific Quality of Life Questionnaire version 
2.1 (MSQ v2.1)(average of Months 4, 5,and 6)
To compare LY2951742 with placebo with respect 
to change i n use o f acut e (abortive )migraine 
treatmentThe overall m ean change from baseline in the 
number of monthly migraine headache days 
requiring medication for the acute treatment of 
migraine or headache during the 6 -month double -
blind  treatment phase
To compare LY2951742 with placebo with respect 
to change in global severity of the migraine 
conditio nMean c hange f rom baseline in the Patient Global 
Impression of Severity (PGI -S) score (average 
of Months 4, 5,and 6)
I5Q-MC-CGAG Clinical Protocol Page 10
LY2951742Summary of Study Design :  
A multi site, randomized, double -blind, parallel, placebo -controlled trial with 4 study periods in patients who meet 
International Classification of Headache Disorders (I CHD )criteria for a diagnosis of migraine as confirmed during a 
prospective baseline period thatdemonstrate sepisodic frequency (4to 14 migraine headache days per month) .
Treatment Arms and Duration:   
Three treatment arms: LY2951742 ( 120mg/month with a 240 mg loading dose at the first injection [administered as 
2 injections of 120 mg at Visit 3] ), LY2951742 (240 mg /month, administered as 2 injections of 120 mg ),and 
placebo.  Following a prospective baseline (30 -40 days) period, eligible patients will be randomized in a 2:1:1 ratio 
to receive placebo, 120 mg/month of LY2951742 , or 240 mg/month of LY2951742, respectivel y, and will begin a 6-
month treatment phase .  This phase will be followed by a 4 -month, post -
treatment phase during which patients will 
no lo nger receiv eany study  medication .
Number of Patients :
The study  will screen an estimated 1557 potential study participants to ensure randomization of approximately 825
patients with episodic migraine. 
Statistical Analysis:
Unless otherwise specified , analy ses will be conducted on an intent -to-treat (ITT) population, which include all 
patients who are randomized and receive at least one dose of investigational product . Patients in the ITT population 
will be analyzed according to the treatment group to which they are randomized. When mean change from baseline 
is assessed, the patient will be included in the analysis only if the patient has a baseline and postbaseline 
measurement.
The primary analysis will evaluate the efficacy of two doses of LY2951742 compared with placebo on the overall 
mean change from baseline in the number of monthly migr aine headache days during the 6- month double -blind 
treatment phase. Migraine headache day will be defined to include both migraine and probable migraine days. The 
primary  analy sis will be performed using a restricted maximum likelihood based mixed models repeated measures 
(MMRM) technique.  The analysis will include the fixed categorical effects of treatment, regio n, month, and 
treatment -by-month interaction, as well as the continuous fixed covariates of baseline number of migraine headache 
days and baseli ne number of migraine headache days -by-visit interaction.  
I5Q-MC-CGAG Clinical Protocol Page 11
LY29517422.Introduction
2.1. Background
Migraine is a chronic, debilitat ing condit ion found to be one of the top 10causes of disabilit y 
expressed as years lived with disabilit y globally (Vos et al . 2012).  However , one study  estimates 
that only a small fract ion of patients receive prevent ive treatment, although more than 25% of 
migraineurs are in need of prevent ive therapy (Rizzoli 2014).  Despite the availabilit y of 
prevent ive medicat ions for migraine, sign ificant needs remain for new treatm ent opti ons wi th 
improved efficacy and tolerabilit y.
Calcitonin gene -related pepti de(CGRP), a 37 -amino acid neuropeptide , is widely expressed 
throughout the central and peripheral nervous sy stem and acts as a local facil itator of 
inflammatory  processes .  CGRP is implicated in the pathophysio logy of migraine and is 
hypothesized to be invo lved in the release o f inflammatory mediators and the transmissio n of
nociceptive (pain) informat ion from intracranial  blood vessels to t he nervous system (Villal ón
and Olesen 2009). In migraineurs, serum concentrations o f CGRP are significant ly elevated 
during migraine attacks (Goadsby et al. 1990; Goadsby and Edvinsson 1993) ,and infusio n of 
CGRP to individuals wit h a history  of migraine can trigger migraine attacks (Lassen et al. 1998, 
Lassen et al. 2002). The n eutraliz ation of CGRP with antibodi es has been shown to modulate 
neurogenic inflammat ion; thus, these ant ibodies may represent a promising pharmaco logic
approach for the prevent ion of  migraine (Investi gator’s Brochure [IB], Section 3.1) .
LY2951742 is a humanized monoclonal ant ibody  that potently  and selectively binds t o CGRP, 
prevent ing CGRP -mediated bio logical effects (IB, Section 3.1).  To date, m ore than 450 clinical 
trial parti cipants have been exposed to LY2951742 at single doses ranging fro m 1 to 600 mg and 
multiple doses up to 300 mg in 5 clinical trials of LY2951742.  In studies of pat ients with 
migraine ( Studi es I5Q -MC-ART1 [ART -01] and I5Q -MC-CGAB [CGAB]), efficacy data have 
demonstrated that LY2951742 had significant ly greater mean reduction s than placebo in 
migraine headache days and other efficacy  parameters.  Across clinical studies of LY2951742, 
assessment of adverse events (AEs) indica tes that LY2951742 has been well tolerated in both 
healt hy subjects and in pat ients with episodi c migraine.  The AEs generally  have been mild to 
moderate in severit y. In two studies of pat ients with migraine, the most frequent ly reported AEs 
included inje ction
-site pain, upper respi ratory  tract infect ion, abdo minal pain, dizziness, 
inject ion-site ery thema, rash, hypertensio n, and nasopharyngit is.  Analyses of laboratory  values 
and cardio vascular mo nitoring of the clinical studies have shown no other clinic ally important 
changes in tested parameters.
2.2. Study Rationale
Study  I5Q-MC-CGAG (EVOLVE -1) will enable a more com prehensive clinical assessment of 
LY2951742 in a patient populat ion for whi ch the drug al ready has shown preliminary evide nce 
of efficacy and sa fety.  Thi sstudy , along wi th astudy  of identical design in pat ients with 
episodic migraine, is intended to provide pivotal  efficacy data to support a registration program 
in patients with migraines.  EVOLVE -1will include 6 months on LY2951742 or pl acebo
I5Q-MC-CGAG Clinical Protocol Page 12
LY2951742followed by 4 m onths of post -treatm ent observat ionto deepen understanding of the effects of a 
CGRP ant ibody  in prevent ing migraines .  
I5Q-MC-CGAG Clinical Protocol Page 13
LY29517423.Objectives and Endpoints
Table CGAG. 1shows the key object ives and endpoints of the study .  Table CGAG. 2provi des 
definit ions for the terms referenced below.
Table CGA G.1. Objectives and Endpoints
Objectives Endpoints
Primary
To test the hypothesis that at least 1 dose of 
LY2951742 (120 or 240 mg/month) is superior to 
placebo in the prevention of migraine headache in 
patients with episo dic migraine.The overall m ean change from baseline in the number of 
monthly migraine headache days during the 6-mo nth 
double -blind treatment phase.
Key Secondary Objectives
If LY2951742 (120 or 240 mg/month ) is statistically 
significantly  superior to placebo on the primary 
objective , the following key secondary objectives will 
be tested w ith adjustment for multiplicity:The specific methodology (including testing order, 
relatio nship and type I error allocation and propagation) 
for the tests of the following key secondary  endpoints will 
be specified in t he statistical analysis plan: 
To compare LY2951742 with placebo with respect 
to 50% response rateThe proportion of patients with reduction from 
baseline ≥50% in monthly  migra ine headache days
during the 6 -month double -blind treatment phase
To compare LY2951742 with placebo with respect 
to 75% response rateThe proportion of patients with reduction from 
baseline ≥75% in monthly  migraine headache days
during the 6 -month double -blind treatment phase
To compare LY2951742 with placebo with respect 
to 100% response rateThe proportion of patients with a 100% reduction 
from baseline in monthly migraine headache days 
during the 6 -month double -blind treatme nt phase
To compare LY2951742 with placebo with respect 
to change in function ingMean change from baseline in the Role Functio n-
Restrictive domain score of the Migraine -Specific 
Quality  of Life Questionnaire version 2.1 (MSQ v2.1)
(average of Months 4, 5,and 6)
To compare LY2951742 with placebo with respect 
to change in use of acute (abortive) migraine 
treatmentThe overall mean change from baseline in the number 
of monthly migraine headache days requiring 
medication for the acute treatment of migrai ne or 
headache during the 6 -month double -blind treatment 
phase
I5Q-MC-CGAG Clinical Protocol Page 14
LY2951742Objectives and Endpoints
Objectives (cont.) Endpoints (cont.)
Key Secondary (cont.)
To compare LY2951742 with placebo with respect 
to change in global severity of the migraine 
conditio nMean change from baseline in the Patient Global 
Impression of Severity (PGI -S) score (average of 
Months 4, 5,and 6)
Other Secondary Objectives
To compare LY2951742 with placebo with respect 
to change in headache daysThe overall m ean change from baseline in the number 
of monthly headache days during the 6- month 
double -blind treatment phase 
To compare LY2951742 with placebo with respect 
to change in moderate to severe headache daysThe overall m ean change from baseline in the number 
of monthly moderate to severe headache days during 
the 6 -month double -blind treatment phase
To compare LY2951742 with placebo with respect 
to 30% response rateThe proportion of patients with reduction from 
baseline ≥30% in monthly migraine headache days 
during the 6 -month double -blind treatment phase
To compare LY2951742 with placebo with respect 
to distribution of response ratesCumulative d istribution of monthly migra ine 
headache day response rates during the 6 -month 
double -blind treatment phase
To compare LY2951742 with placebo with respect 
to time to 50% responseTime to first occurrence of a ≥50% reduction from 
baseline in the number of monthly migraine headache 
days (Kaplan -Meier analysis) 
To compare LY2951742 with placebo with respect 
to onset of effectTheinitial month at which statistical separation in 
mean change from baseline in the number of monthly 
migraine headache days is demonstrated and 
maintained at all subsequent months throug h Mo nth 6
To compare LY2951742 with placebo with respect 
to onset of 50% sustained responseThe initial month at which statistical separation in the 
propor tion of patients meeting at least a 50% 
reductio n in monthly migraine headache days that is 
mainta ined at all subsequent months through 
Month 6
I5Q-MC-CGAG Clinical Protocol Page 15
LY2951742Objectives and Endpoints
Objectives (cont.) Endpoints (cont.)
Other Secondary Objectives (cont.)
To compare LY2951742 with placebo with respect 
to maintenance of 50% responseThe proportion of patients who maintain 50% 
response criteria for at least 3 consecutive months to 
the patient’s endpoint and the proportion of patients 
who maintain 50% response criteria for 6 
consecutive months during double -blind treatment
To compare LY2951742 with placebo with respect 
to changes in other efficacy parameters, 
specifically:
oInternational Classification of Headache 
Disorders (ICHD) migraine headache days
omigraine attacks
omigraine headache hours
oheadache hours
oseverity  of remaining migrainesOverall m ean change from baseline ( during the 6 -
month double -blind treatment phase ) on the 
following monthly  measures:
oInternational Classification of Headache 
Disorders (ICHD) migraine headache days
omigraine attacks
omigraine headache hours
oheada che hours
oseverity  of remaining migraines
To compare LY2951742 with placebo with respect 
to global assessment of illnessOverall mean Patient Global Impression -
Improvement (PGI -I) rating during the 6 -month 
double -blind treatment phase
To compare LY2951742 with placebo with respect 
to changes in disability and quality of lifeMean change from baseline on the following 
measures:
othe Migraine Disability Assessment test 
(MIDAS) total score and individual items at 
Month 6
othe Migraine -Spec ific Quality of Life 
Questionnaire, version 2.1 (MSQ v2.1) total 
score, and Role Function-Pr eventive and 
Emotio nal Function domain scores (average of 
Months 4, 5,and 6)
To compare LY2951742 with placebo with respect 
to safety and tolerabilityAnaly sisof:
otreatment -emergent adverse events ( TEAEs )
odiscontinuation rates
ovital signs and weight
oelectrocardiograms (ECGs)
olaborato ry measures
oother safety parameters, including suicidality 
using the Columbia -Suicide Severity Rating 
Scale (C -SSRS)
I5Q - MC- CGAG  C l in ica l  P ro toco l Page  16
LY2951742Ob j e c t i v e s  and  Endp o in t s
Ob j e c t i v e s( c on t . ) Endp o in t s( c on t . )
O th e r  S e c ond a r y  Ob j e c t i v e s( c on t . )
 T o  e v a l u a t e  LY 2 9 5 1 7 4 2  w i t h  r e s p e c t  t o  
i mm u n o g e n i c i t y T h r o u g h o u t  t h e  s t u d y :
o De v e l o pm e n t  a n d  c o n s e q u e n c e s  o f  a n t i - d ru g  
a n t i b o d i e sa n d  n e u t r a l i z i n g  a n t i - d r u g  a n t i b o d i e s
t o  LY 2 9 5 1 7 4 2  
 T o  e v a l u a t e  LY 2 9 5 1 7 4 2  w i t h  r e s p e c t  t o  
p h a rm a c o k i n e t i c s Se r um  c o n c e n t r a t i o n s  o f  LY 2 9 5 1 7 4 2
 T o  e v a l u a t e  LY 2 9 5 1 7 4 2  w i t h  r e s p e c t  t o  
p h a rm a c o d y n am i c s( t a r g e t  e n g a g em e n t ) Pl a sm a  c o n c e n t r a t i o n s  o f  CGRP
 T o  a s s e s s  c h a n g e s  i n  e f f i c a c y  o u t c om e s  d u r i n g  
S t u d y  P e r i o d  IV  a s  c o l l e c t e d  b y  e l e c t r o n i c  p a t i e n t-
r e p o r t e d  o u t c om e s  ( ePRO )  d i a r y  d a t a In  S tudy  P e r i o d  IV :
o M e a n  c h a n g e  f r om  b a s e l i n e  i n  m o n t h l y  
m i g r a i n e  h e a d a c h e  d a y s
o T im e  t o  f i r s t  l o s s  o f  r e s p o n s e  am o n g  p a t i e n t s
w ho  m e t  t h e  5 0%  r e s p o n s e  r a t e  c r i t e r i a  a t  t h e  
e n d  o f  t h e  d o u b l e - b l i n d  t r e a tm e n t  p h a s e
o T im e  t o  i n i t i a t i o n  o f   t r e a tm e n t  w i t h  a  m i g r a i n e  
p r e v e n t i o n  m e d i c a t i o n
T e r t i a r y  Ob j e c t i v e s
 T o  e x p l o r e  t h e  e f f e c t  o f  LY 2 9 5 1 7 4 2  o n  n o n-
m i g r a i n e  c h r o n i c  p a i n M e a n  c h a n g e  f r om  b a s e l i n e  i n  a v e r a g e  p a i n  s e v e r i t y  
o f  o t h e r  c h r o n i c  p a i n  c o n d i t i o n s
 T o  c om p a r e  LY 2 9 5 1 7 4 2  w i t h  p l a c e b o  w i t h  r e s p e c t  
t o  c a t e g o r i c a l  c h a n g e s  i n  q u a l i t y  o f  l i f e P e r c e n t a g e s  o f  p a t i e n t s  w i t h :  
o ≥ 5 0%  im p r o v em e n t  i n  M IDAS  t o t a l  s c o r e
o c h a n g e  f r om  b a s e l i n e  i n  MSQ  R o l e  F u n c t i o n -
R e s t r i c t i v e  d om a i n   ≥ 1 0 . 9  
o c h a n g e  f r om  b a s e l i n e  i n  MSQ  R o l e  F u n c t i o n -
P r e v e n t i v e  d om a i n   ≥ 8 . 3
o c h a n g e  f r om  b a s e l i n e  i n  MSQ  Em o t i o n a l  
F u n c t i o n  d om a i n   ≥ 1 2 . 2
 T o  c om p a r e  LY 2 9 5 1 7 4 2  w i t h  p l a c e b o  w i t h  r e s p e c t  
t o  t h e  p ro p o r t i o n  o f  m i g r a i n e  h e a d a c h e  d a y s  
r e q u i r i n g  m e d i c a t i o n  f o r  t h e  a c u t e  t r e a tm e n t  o f  
m i g r a i n e  o r  h e a d a c h e Ch ang e  fro m  b a s e l i n e  i n  t h e  p r o p o r t i o n  o f  mon th ly 
m i g r a i n e  h e a d a c h e  d a y s  r e q u i r i n g  m e d i c a t i o n  f o r  
t h e  a c u t e  t r e a tm e n t  o f  m i g r a i n e  o r  h e a d a c h e  CC I
I5Q-MC-CGAG Clinical Protocol Page 17
LY2951742Objectives and Endpoints
Objectives (cont.) Endpoints (cont.)
Tertiary Objectives
To compare LY2951742 with placebo with respect 
to changes in symptomatology associated with 
migraine or probable migraine Change f rom baseline in the number of monthly 
migraine headache days with:
onausea and/or vomiting
ophotophobia and phonophobia
oaura
oprodromal symptoms other than aura
Table CGA G.2. Migraine and Headache Endpoint Definitions
Diagnosis Definition/Criteria
Migraine headache Aheadache, with or without aura, of ≥30 minutes duratio n
with both of the following required features (A and B) :
A. At least 2 of the following headache characteristics:
Unilateral location
Pulsatile quality
Moderate or severe pain intensity
Aggravatio n by or causing avoidance of routine 
physical activity
AND
B. During headache at least one of the following: 
Nausea and/or vomiting
Photophobia and phonophobia
(Definition adapted from the Standard I nternational 
Headache Society [ IHS] International Classification of 
Headache Disorders (ICHD) -3 beta)
Probable migraine A headache missing 1 of the migraine features in the IHS 
ICHD -3 beta definition such that one feature in criteria A is 
missing or one feature in criteria B is missing; that is ,meet at 
least 2 A criteria and none of the B criteria or meet 1 of the A 
criteria and at least 1 of the B criteria.
Migraine headache day (primary  objective) A calendar day on which a migraine headache or probable 
migraine headache occurred.
Migraine h eadache attack Beginning on any  day a migraine headache or probable 
migraine headache is recorded and ends w hena migraine -free
day occurs.
Non-migraine headache All headaches of at least 30 minutes duration not fulfilling 
the definition of migraine or pr obable migraine are classified 
as non -migraine headaches.
I5Q-MC-CGAG Clinical Protocol Page 18
LY2951742Migraine and Headache Endpoint Definitions
Diagnosis (concluded ) Definition/Criteria (concluded )
Non-migraine headache day A calendar day on which a non -migraine headache occurred.
Headache day A calendar day on which any type of headache occurs 
(including migraine headache, probable migraine headache ,
and no n-migraine headache).
I5Q-MC-CGAG Clinical Protocol Page 19
LY29517424.Study  Design
4.1. Overview of Study Design
Study  CGAG (EVOLVE -1) is a Phase 3, mult isite, double -blind, rando mized, pla cebo -
controlled, study  ofLY2951742 in pat ients suffering fro m episodi c migraine. The study  has4 
periods, including a prospective baseline phase to determine patient eligibilit y.  
Figure CGAG. 1illustrates the study design.
Figure CGA G.1. Illustration of study design for Clinical Protocol I5Q-MC-CGAG .
Study Period I: The study and potential risks will be explained to the patientat Visit 1.  The 
inform ed consent form (ICF) must be signed before any study  procedures are perform ed.  
Patients are requi red to di scont inue all excluded medicat ions or migraine prevention treatments 
at least 30 days prior to Visit 2.  Botulinum to xin A or B in the head or neck area must be 
discontinued at least 4 months prior to Visit 2.
The screening visit (Visit 1) will consist of a full clinical assessment, including a comprehensive 
medical evaluat ion docum enting medical history , and a physical and neuro logical examination
(Appendix 2 ).  Visit 1 will be co mplete when the last scheduled procedure of the screening 
assessment i s completed.  

I5Q-MC-CGAG Clinical Protocol Page 20
LY2951742Study Period II : Qualified pat ients will enter Study  Period II ( prospective baseline ) to 
determine their eligibilit y for the study  and to establish baseline data for comparison of endpo ints 
during the treatment period.   Beginning at Visit 2, pati ents will  log in daily to the electronic 
patient-reported outcomes ( ePRO) system  to answer que stions about the occurrence of 
headaches, headache duration, headache features , severit y of headache, and use of headache 
medicat ion.  At the end of the prospective baseline period, siteswill be notified whether their 
patients m et criteria a nd are eligibl e to be randomized at Visit 3.  
To avoid biased reporting, patients must not be told the number of migraine headache days 
on which study qualification is based.
Study Period III :At the start of the 6 -month,double -blind treatment p hase ( Visit 3),patients 
meet ing all eligibilit y requi rements will be randomized to 1 of 3treatm ent groups in a 2:1:1 ratio 
to receive placebo, 120 mg/mo nth LY2951742 , 
or 240 m g/month LY2951742, respect ively.   
Patients randomized to the 120 mg dose of LY2951742 will re ceive an init ial loading dose of 
240 m g (2 inject ions of 120 m g each at Vi sit 3 only ).To preserve blinding throughout the study, 
patients in all treatm ent groups will receive 2 injections of invest igational product at each dosing 
visit.  At Visit 3, if available and where local regulations and Ethical Review Boards allow, 
patients will  also watch a training video designed to address patient expectations wit h regard to 
participat ion in a placebo -controlled trial and the difference between medical treatment and 
research.  
The patient will be considered enrolled in the study when rando mizat ion occurs.  During this 
phase , study  procedures at dosing visits must al ways occur pri or to the pati ent receiving their 
assigned treatment .  
Patients will  be given injec tions of  invest igational product during office visits (Figure CGAG. 1).  
For all treatment groups, subcutaneous inject ionswill be administered once monthly at the 
dosing visits.   
At Visi t 3(first dose) , pati ents will be requi red to rem ain in the office for 
observat ionfor 30 minutes post inject ion.  Patients will cont inue to log in and com plete the 
ePRO diary each day .  Pati ents m ay cont inue to take thei r allowed acute migraine headache 
medicat ion(with som e limi tations;see concomitant medicat ionsstudy  tool)during the treatment 
phase.   
Patients who com plete th is phase or discont inue for any  reason during Study  Period III will be 
expected to enter post -treatm ent follow-up (Study  Peri od IV).  
Study Period IV : During this 4 -monthphase, s ites and patients wi ll remain blinded to patients’ 
treatm ent assi gnments.  Pati ents will  follow all study  procedures during S tudy Period IV but will 
not receive LY2951742 or placebo. One month after Visit 12, if clinically warranted due to a 
worsenin g of symptom s, patients m ay start mi graine preventi on medicat ions at the discretion of 
the invest igator.  The list of allowed prevent ive medications is provided in theconcomitant 
medicat ions study  tool.  At Vi sit 14 (Month 10), pati ents will return to the si te for thei r last stud y 
visit and discharge fro m the study .  
I5Q-MC-CGAG Clinical Protocol Page 21
LY29517424.2. End of Trial Definition
End of the trialis the date of the last visit or last scheduled procedure shown in the Schedule of 
Activities(Appendix 2 )for the last patient.
4.3. Scientific Rationale for Study Design
The l ength of the rando mized treatment phase is considered suffic ientto assess the safet y and 
efficacy  of a migraine prevent ion medicat ionand is consistent with regulatory  feedback .A 4-
month post -treatm ent follow-up phase is included to evaluate patient safety  during wash -out of 
LY2951742. This allows for a total of 5 months of observat ion from the time of last inject ion of 
LY2951742.  A 5-month post -treatment observat ion peri od all ows f or a wash -out of 
approximately  5 eliminat ion half-lives of LY2951742 and should decrease LY2951742 serum 
concentrations by approximately 97% during this time. 
4.4. Justification for Dose
Doses of120and240 m
g administered once monthly were selected primarily on the basis of 
clinical efficacy  and pharmacokinet ic/pharmacodynamic data fro m the Phase 2 dose -ranging 
study .  Results fro m the Phase 2 dose-ranging study indicate that 120 mg was statistically 
significant ly superi or to pl acebo at the l ast 28 -day period of the 3 -month treatm ent phase in 
mean change in migraine headache days, as well as in other measures of efficacy and qualit y of 
life. The use of a loading dose for the 120 mg treatm ent arm , and the inclusio n of a 240 mg 
treatm ent arm, is based on the finding that a dose higher than 120 m g achieved statistically 
significant separati on from placebo as early as Month 1.  The pl anned doses of 120 m g and 
240mg LY2951742 for Study  CGAG also are being evaluat ed in two other pivotal efficacy 
studi es of  LY2951742; one of these studies is in patients with episodic migraine, and one is in 
patients wi th chroni c migraine.
4.5. Benefit/Risk Assessment
More i nform ation about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated adverse events (AEs) of LY2951742 are to be found in th e 
Invest igator’s Brochure (IB).
I5Q-MC-CGAG Clinical Protocol Page 22
LY29517425.Study  Population
All patients must meet the fo llowing select ion criteria.  Eligibilit y of patients for study  
enrollment will be based on the results of a screening medical history, physical examinat ion, 
neuro logical examinati on, clinical laboratory  tests, electrocardi ograms ( ECG s), and migraine 
history  during screening and aprospective baseline period, as described in the Inclusio n and 
Exclusio n Cri teria sect ions.  The nature of any comorbid condit ions present at the time of the 
physical examinat ion and any  pre-exist ing condit ions must be documented.   Individuals who do 
not m eet the cri teria for parti cipat ion in this study  (screen failure) for specific reasons as outlined 
may be considered for rescreen ingonce, wi th approval  from Eli Lilly and Co mpany ( Lilly )
Medical (Sect ion 5.3).
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study or 
for 5 m onths f ollowing last administration of investi gational product .
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
5.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at
screening :
Patient and Disease Characteristics
[1] Patients are 18 to 65 y ears of age (inclusive) at the time of screening .
[2] Have a diagnosis of migraine as defined by  Internati onal Headache Soci ety 
(IHS) International Classificat ion of Headache Disorders (ICHD) -3 beta 
guidelines (1.1 or1.2) ( ICHD -3 2013) , witha history  of migraine headaches
of at least 1 year prior to Visit 1 , and migraine onset prior to age 50.   
[3] Prior to Vi sit 1, have a history  of 4 to 14 migraine headache days and at least 
2 migraine attacks per month on average within the past 3 months .
[4] From  Visi t 2 to Visi t 3 (prospective baseline period), have a frequency of 4 to 
14 migraine headache days and at least 2 migraine attacks (see definit ions, 
Table CGAG. 2
). To avoid biased reporting, patients must not be told the 
number of migraine headache days on which study qualification is based.
[5] From  Visi t 2 to Visi t 3 (prospective baseline period), must achieve sufficient 
compliance wi th ePRO daily headache entries as demonstrated by  com pletion 
of at least 80% of daily diary  entries.
Informed Consent and Patient Agreements
[6]Are able and willing to give signed informed consent.
[7] Are reliable an d willing to follow study  procedures, including all fo llow-up 
visits.
I5Q-MC-CGAG Clinical Protocol Page 23
LY2951742[8] Women of child- bearing potenti almust test negative for pregnancy  at the time 
of enro llment based on a serum pregnancy test .
[
9]All patients, male and female, must agree to use a reliable method of birth 
control  during the study as well as for 5 months after the last dose of 
investigat ional product .  Acceptable methods of birth control for this study 
include: oral contraceptives; implantable contraceptive s; injectable 
contraceptive s; a contraceptive patch; barrier methods such as diaphragms 
with contracepti ve jelly, cervical caps wit h contraceptive jelly, condo ms with 
contraceptive foam, or intrauterine devices; a partner with vasectomy. Birth 
control  is not requi red if the f emale isinfertile due to surgical sterilizat ion (at 
least 6 weeks after surgical bilateral oophorectomy , hysterectomy ,or at least 6 
weeks after tubal  ligat ion) confirmed by medical history  or m enopause.  
Menopause is defined as spontaneous amenorrhea for at l east 12 m onths not 
induced by  a medical condi tion, or spontaneous amenorrhea of 6 -12 m onths 
and a fo llicle st imulating hormone level >40 mIU/mL.
[
10] A gree not to post any  personal medical data rel ated to the study  or 
inform ation related to the study  on an y websi te or soci al media si te (for 
example, Facebook, Twitter, LinkedIn, Google +, etc.) until the entire trial has 
completed.
5.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at
screening:
Prior/Concurrent Clinical Trial Experience
[11]
Are current ly enrolled in any other clinical trial invo lving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study .  
[12]
Have part icipated within the last 30 day s or wi thin 5 half -lives (whichever is 
longer) in a clinical trial invo lving an invest igational product.  If the 
investigat ional product’s half-
life is not known, 6 mo nths should have passed 
prior to Visit 1.
[13] Current use or prior exposure to LY2951742 or another CGRP antibody , 
including those who have previously completed or withdrawn from this study  
or any  other study  invest igating a CGRP antibody .
I5Q-MC-CGAG Clinical Protocol Page 24
LY2951742Prior/Concomitant Therapy
[14]Patients who are taking , or are expected to take, therapeuti c ant ibodies during 
the course of the study  (for example, adalimumab, infliximab, trastuzumab, 
bevacizumab, etc.).  Prior use of therapeutic ant ibodies , 
other than antibodies 
to CGRP or i ts receptor, is allowed ifthat use was more than 12 m onths prior 
to Visit 2.
[15] Known hypersensit ivity to mu ltiple drugs, m onoclonal  antibodies or other 
therapeuti c proteins, or to LY2951742 .
[16] Are current ly receiving medicat ion or other treatments for the prevent ion of 
migraine headaches.  Patients must have discont inued such treatment at least 
30 day s prior to Vi sit 2.  Botulinum  toxin A and B that has been administered 
in the head or neck area must be di scont inued at least 4 months prior to 
Visit 2.
[17] Failure to respond to 3or more adequately dosed migraine prevent ive 
treatm ents fro m different classes (that is, maximum tolerated dose for at least 
2 months). Failure to respond due to tolera bility issues is not considered a 
treatm ent failure.  M igraine prevent ivetreatm ents are defined as Level A and 
Level B in Table 1 of the American Academy of Neurology ’s Evidence -based 
Guidelines Update:  Pharmaco logic Treatm ent for Episodi c Migraine 
Preve ntion in Adults (Silberstein et al. 2012 )as well as botulinum toxin A or 
B
.
Diagnostics Assessments
[18] History  of persistent daily  headache, cl uster headache or migraine subt ypes 
including hemiplegic (sporadic or familial) migraine, ophthalmoplegic 
migraine, and migraine with brainstem  aura (basilar -type migraine) defined by 
IHS ICHD -3 beta.
[19] History  of headache (for example, cluster headache, Medicat ion Overuse 
Headache) other than migraine or tensio n type headache as defined by  IHS 
ICHD -3 beta wit hin 3 mo nths prior to randomization.  
[20] Prior to Vi sit 1, a history  of ≥15 headache days (migraine, probable migraine 
orany other headache) per m onth on average during the past 3 months or are 
suspected of suffering fro m chronic migraine as defined per ICHD -
3 beta.
[21] History  of head or neck injury  within 6 m onths prior to Vi sit 1.
[22] Patients wi th a history  of traum atic head injury associated with significant 
change in the qualit y or frequency of their headaches should be excluded.
I5Q-MC-CGAG Clinical Protocol Page 25
LY2951742Medical Conditions
[23] Have ECGs showing abnorm alities com patible wit h acute cardiovascular 
events and/or serious cardiovascular risk, including but not limited to a 
corrected QT (QTcB [Bazett's ]) interval > 470 m sec for wom en and >450 for 
men, or havehad my ocardial  infarcti on, unstable angina (UA), percutaneous 
coronary  intervent ion, coronary  artery  bypass graft, stroke, or deep vein 
thrombosis/pulmo nary embo lism wit hin 6 months of screening, or have 
planned cardio vascular surgery or percutaneous coronary  angi oplasty .
[24] Patients wi th a body  mass index ≥40 kg/m2.
[
25]Any liver tests outsi de the norm al range at Vi sit 1 that are clinically 
significant. A lanine aminotransferase (ALT) >2X upper limit of norm al 
(ULN), ortotal bilirubin (T BL)>1.5X U LN, or alkaline phosphatase (ALP) 
>2X ULN m ust be discussed and judged not clinically significant by  Lilly  
Medical prior to enrollment .
[26] Evidence of significant active or unstable psychiatri c disease by medical 
history , such as bipo lar disorder , schizo phrenia, personalit y disorders, or other 
serious moodor anxiet y disorders. Note : Patients with major depressive 
disorder or generalized anxiet y disorder whose disease state is considered 
stable and expected to remain stable throughout th e course of the study , in the 
opinio n of the invest igator, may be considered for inclusio n if they are not on 
excluded medicat ions.
[27] Patients who, in the clinician’s judgment, are actively suicidal and therefore 
deem ed to be at si gnificant ri sk for sui cide, or those w ho have answered “yes”
to either Question 4 (Act ive Suicidal Ideat ion with Som e Intent to Act, 
Without Specific Plan) or Question 5 (Act ive Suicidal Ideation wit h Specific 
Plan and Intent) on the “Suicidal  Ideat ion”porti on of  the C olumbia –Suicide 
Severit y Rating Scale (C
-SSRS), or answer “yes”to any  of the sui cide-related 
behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory  
act or behavior) on the “Suicidal Behavior” porti on of  the C –SSRS; and the 
ideat ion or behavio r occurred wi thin the past m onth.
[28] Women who are pregnant or nursing.
[29] Patients who have used opioids or barbiturate containing analgesic >2 Xper 
mont
h for the treatment of pain in more than 2 of the past 6 months (opioid 
administration in an emer gency  setti ng may be an exception) .
[30] History  of drug or alcoho labuse/dependence wit hin 1 y ear pri or to Vi sit 1 
(excessive or compulsive use as judged by  the Investi gator), or currently using 
drugs of abuse (including opio ids, barbiturates and marijuan a), or any  
prescribed or over- the
-counter medicat ion in a manner that the Investigator 
considers indicat ive o f abuse/dependence.
I5Q-MC-CGAG Clinical Protocol Page 26
LY2951742[31] Have a posit ive urine drug screen for any  substances of abuse at Visit 1 .  
Note : A retest is allowed if the urine drug scr een is posi tive for any  prescribed 
substance or if, in the judgment of the invest igator, there is an acceptable 
explanat ion for the posit ive result .  The results of the retest must be negat ive 
ator prior to Visit 2 .
[
32]Have a history  or presence of any other medical  illness including but not 
limited to any  autoimmune disorder, cardiovascular, hepatic, respiratory , 
hematol ogical, endocrine, psychiatric or neurological disease, or any  clinically  
significant laboratory  abnorm ality, that in the judgme nt of the investigator, 
indicates a medical problem that woul d preclude study  parti cipat ion.
Other Exclusions
[33] In the opinion o f the invest igator have other issues which would interfere with 
compliance wi th the study  requi rements and com pletion of  eval uations 
requi red for thi s study .
[34]
Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted .
[35]
Are Lilly  empl oyees.
[36]
Are unwilling or unable to comply  with the use of a data collect ion device .
5.3. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be
considered for rescreen once, wi th approval  from Lilly Medical  for only  the cri teria shown 
below.  The interval between screening and rescreening mustbe at l east 45 days or longer if 
requi red for the specified timeframes in the inclusion/exclusion criteria or concomitant 
medica tion list .  If rescreening is performed, the individual must si gn a new ICF and will be 
assigned a new ident ificat ion number.
Inclusio n criterion 1.  If pati ents are l ess than age 18 at time of informed consent, 
they may be rescreened if they reach age 18 during the study enro llment period.
Inclusio n criterion 
8
Exclusio n criterion 12
Exclusio n criterion 14
Exclusio n criterion 
16
Exclusio n criterion 28
Patients using a concomitant medicat ion that requires a stable dose for a specific durat ion prior 
to Visit 2 may be rescreened if addit ional time is needed to meet the duration requirement .
I5Q-MC-CGAG Clinical Protocol Page 27
LY2951742In addit ion, after consultation wit h and approval by a Lilly Medical representative, a patient may 
be rescreened if there is an unexpected technical difficult y with the electronic di ary capture 
during the prospective baseline period .
5.4. Lifestyle and/or Dietary Requirements
No changes in lifestyle or dietary  requi rements are requi red during the study .However, patients 
must be in a fast ing state for collect ion of laborato ry samples at selected visit s specified in 
Appendix 2 .
I5Q-MC-CGAG Clinical Protocol Page 28
LY29517426.Treatment
6.1. Treatments Administered
This study  involves a comparison of LY2951742 ( 120and 240 mg) administered once monthly
with placebo.   Sites will  administer inject ionsof investi gational product (LY2951742 and/or 
placebo) at6 office visits during the treatment p hase (Appendix 2 ). 
Possible inject ion sites include the abdo men, thi gh, and upper arm .  Buttocks may  also be used, 
if needed . 
The invest igator or his/her designee is responsible for the fo llowing:
maintaini ng accurate records of investigational product dispensing
at the end of the study  returning all unused medication to Lilly ,or its desi gnee ,
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by the site, as allowed by local law.
6.1.1. Medical Devices
The m anufactured medical devices provided for use in the study  areprefilled syringes.
6.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to double -blind treatment at
Visit 3.  Assignment to treatm ent groups w ill be determined by a computer -generated random 
sequence using an interactive web -response system (IWRS).   The IWRS will be used to assi gn
doubl e
-blind investigat ional product to each patient. Site personnel will confirm that they  have
located the correct lyassigned package by entering the confirmat ion number found on the
package into the IWRS.
To achieve between -group com parabilit y, the randomizat ion will be stratified by  region and 
baseline migraine frequency (<8 migraine headache day s versus ≥8 migraine headache days). To 
ensure an appropriate balance o f low-and high -frequency migraine headache day patients, the
sponsor willstop enrollment oflow-frequency patients ifthenumber exceeds anestimated 578.
6.2.1. Selection and Timing of Doses
This is a fixed- dose study .  The actual time of all dose administrations will be recorded in the 
patient’s electroni c case report form ( eCRF).
6.3. Blinding
This is a double -blind study .
To preserve the blinding of the study , a minimum number of Lilly  personnel  will see the 
rando mizat ion table and treatment assignments before the study  is complete.
I5Q-MC-CGAG Clinical Protocol Page 29 
LY2951742 Emergency unblinding for AEs may be performed through the IWRS.  This option may be used 
ONLY if the patient’s well-being requires knowledge of the patient’s trea tment assignment.  All 
unblinding events are recorded and reported by IWRS. 
If an investigator, site personnel performing a ssessments, or patient is unblinded, the patient 
must be discontinued from the study.  In cases wh ere there are ethical reas ons to have the patient 
remain in the study, the investigator must obtain specific approval from a Lilly clinical research 
physician (CRP) or clinical res earch scientist (CRS) for the pa tient to continue in the study. 
In case of an emergency, the inve stigator has the sole  responsibility for de termining if unblinding 
of a patient’s treatment assignm ent is warranted.  Patient safe ty must always be the first 
consideration in making such a determination.  If the investigator de cides that unblinding is 
warranted, the investigator should make every e ffort to contact the L illy CRP/CRS prior to 
unblinding a patient’s treatment a ssignment.  If a patient’s trea tment assignment is unblinded, 
Lilly must be notified immediately. 
6.4. Packaging and Labelling 
LY2951742 and matching placebo (excipients only) will be supplied as an injectable solution in 
1-mL, single-dose, prefilled, disposable manual syri nges with study specific labels.  Each syringe 
of LY2951742 is designed to deliver LY 2951742 120 mg.  The syringes (and contents) 
containing either LY2951742 or placebo will be  visibly indistinguishable from each 
other.  Syringes will be supplied in cartons, with  the appropriate quantity of syringes specific to 
the planned dispensing schedule of investigational product. 
Clinical trial materials will be labeled according to the country’s regulatory requirements.  
6.5. Preparation/Handling/Storage 
Investigational product will be shipped (as prefilled syringes)  to sites using cold chain 
transportation.  Investigati onal product must be stable and stored  in a refrigerator at 2ºC to 8ºC 
(35.6ºF to 46.4ºF).  Approximately 30 minutes prior to administration, the syringe should be removed from the 
storage area and allowed to e quilibrate at ambient conditions.  The drug product should be kept 
away from direct exposure to bri ght light (such as sunlight) and hot  surfaces until administration. 
6.6. Dose Modification 
Dose modifications are not permitted in this study.  
6.6.1. Special Treatment Considerations 
During the post-treatment follow-up period, pa tients will not receive LY2951742 or placebo.  
One month after Visit 12, if clin ically warranted due to a worsening of symptoms, patients may 
start migraine prevention medications at the disc retion of the investigator.  The list of allowed 
preventive medications is provided separately. 
I5Q-MC-CGAG Clinical Protocol Page 30
LY29517426.7. Treatment Compliance
Invest igators will be required to document the administration of invest igational product in the 
eCRF.
Invest igational product must be administered as indi cated in the Schedule of Act ivities
(Appendix 2 ).  If the invest igator is unable to administer the investigational product in the 
allowed window, the situation shoul dbe discussed with Lilly to determine if the patient may  
continue .
6.8. Concomitant Therapy
The list of medicat ions allowed or not allowed for the acute treatment of migraine, as well as 
those prohibited for the prevent ion of migraine, is provided inthe concomitant m edicat ion list in 
the concomitant medications study  tool, along wi th all  concomi tant therapies allo wed or not 
allowed during the study .Note that there are some limitat ions regarding conco mitant 
medicat ions for the acute treatment of mig raines during the study .  Any changes in the list of 
allowed/not allowed medications will be communicated to invest igators and will not constitute a 
protocol  amendment.
6.9. Treatment after Study Completion
6.9.1. Study Extensions
Not applicable.
6.9.2. Continued Access
Invest igational product will not be m ade available to patients after concl usion of the study .
I5Q-MC-CGAG Clinical Protocol Page 31
LY29517427.Discontinuation Criteria
Patients who discont inue t he study or invest igational product during the doubl e-blind treatment 
phase ( Study  Period III )will proceed immediately to Study  Period IV.
7.1. Discontinuation from Study Treatment
7.1.1. Permanent Discontinuation from Study Treatment
Discontinuati on of  the invest igational product for abnormal liver tests should be considered by 
the invest igator when a pat ient meets one of the fo llowing condi tions af ter consul tation wi th the 
Lilly designated medical mo nitor:
ALT or aspartate aminotransferase (AST) >8X ULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and TBL >2X ULN or prothrombin t ime >1.5X ULN
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ALP >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5XULN with the appearance of fatigue, nausea, vo miting, r ight quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Patients who discont inue the invest igational product early  will have end -of-therapy  (early 
termination) procedures performed as shown in the Schedule of Activit ies(Appendix 2 )and are 
requested to proceed into the post -treatm ent phase .
7.1.2. Temporary Discontinuation from Study Treatment
Not applicable.
7.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ify a pat ient who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between thesponsor CRP /CRS and the 
investigator to determine if the pat ient may continue in the study .  If both agree i t is medically  
appropriate to continue, the invest igator must obtain documented approval fro m the sponsor 
CRP /CRS to allow the inadvertent ly enro lled patient to continue in the study  with or wi thout 
treatm ent wi th invest igational product.
7.1.4. Permanent Discontinuation from the Study
Some possible reasons that may  lead to perm anent di scontinuat ion include:
I5Q-MC-CGAG Clinical Protocol Page 32
LY2951742Enrollment in any other clinical trial invo lving an investigational product or enrollment in 
any other ty pe of medical research j udged not to be sci entifically or medically co mpat ible 
with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the patient should be discontinued from the study
oif the pat ient, for any  reason, requi res treatm ent with another therapeutic agent that 
has been demonstrated to be effect ive for the study indication (preventi on of  
migraine) during Study  Period III ,discontinuat ion from the study  occurs pri or to 
introducti on of  the new agent
Subject Decisio n
othe patient asks to be wi thdrawn from  the study
Patients who discont inue the study early will have end -of-study  (early  terminati on) procedures 
perform ed as shown in the Schedule of Act ivities(Appendix 2 )and are requested to proceed into 
the post -treatment p hase.
7.1.5. Patients Lost to Follow -Up
A pat ient willbe considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I5Q-MC-CGAG Clinical Protocol Page 33
LY29517428.Study  Assessments and Procedures
Appendix 2 lists the Schedule of Act ivities, with the study procedures and their timing (including 
tolerance limit s for timing).
Appendix 3 lists the laboratory tests that wi ll be perform ed for this study .
Appendix 4 lists the tests that ma y be obtained in the event of a treatment -emergent hepatic 
abnorm ality.
Unless otherwise stated in the subsect ions below, all samples co llected for specified laboratory
tests will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
8.1. Efficacy Assessments
8.1.1. Prima ry Efficacy Assessments 
ePRO Di ary:  Pati ents will be asked to use an ePRO device (starting at Visit 2) to record 
headache symptom s, durati on, and severit y.  The device also will be used to collect the name and 
dose of conco mitant m edicat ions used for the acute treatment of migraine, and the use of other 
pain medicat ions.
8.1.2. Secondary Efficacy Assessments 
8.1.2.1. Patient Global Impression of Severity
The Pati ent Gl obal Impressi on of Severi ty (PGI -S) scale ( Guy 1976) is a pati ent-rated instrument 
that measures baseli ne illness severit y.  The PGI -S includes a range of possible responses, fro m 1 
(“normal, not at all ill”) to 7 (“extremely ill”).
8.1.2.2. Patient Global Impression of Improvement
The Pati ent Gl obal Impressi on of Improvement (PGI -I) scale ( Guy 1976) i s a patient -rated
instrum ent that m easures improvement of the patient’s symptoms.  It is a 7- point scale in which a 
score of 1 i ndicates the patient is “very  muchbetter ,” a score of 4 indicates the patient has 
experienced “no change,” and a score of 7 indicat es the pati ent is “very  much worse.”
8.1.3. Appropriateness of Assessments
All efficacy and safet y assessments have been well documented and are generally  regarded as
reliable, accurate, and relevant in this pat ient population .  This includes health outcom es 
meas ures considered to be appropriate for evaluat ing changes in qualit y of life, global 
funct ioning, and disabilit y(Secti on 8.9).
I5Q-MC-CGAG Clinical Protocol Page 34
LY29517428.2. Adverse Events
Invest igators are responsible for monitoring the safety of pat ients who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of pat ients during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are seri ous or otherwi se medically  important, considered rel ated to the invest igational 
product or the study , or that caused the patient to discontinue the invest igational product before 
completing the study.  The patient should be fo llowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study  is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via eCRF the occurrence and nature of 
each patient’s pre-exist ing condit ion(s), including clinically significant signs and sympto ms of 
the disease under treatment in the study .  In addit ion, site personnel will record via eCRF any 
change in the condit ion(s) and any new condit ion(s)asAEs. Invest igators should record their 
assessment of the potential relatedness of each AE to proto col procedure orinvest igational 
product via eCRF .
The invest igator will decide whether he or she interprets the observed AEs as reasonably 
possibly  related to migraine headache , to the investigat ional product, study  device, study  
procedure, or other concomitant treatment or pathologies.
The invest igator will answer y es/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has wor sened during the course of the study.
If a patient’s investigational product is discontinued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via eCRF , clarifying if possible, the circumstances 
leading to discontinuations of treatment. 
8.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
I5Q-MC-CGAG Clinical Protocol Page 35
LY2951742congenital ano maly/birth defect
considered significant by  the invest igator for any other reason:  important medical 
events that may  not resul t in death, be life-threatening, or require hospitalization 
may be considered serious, based upon appropriate medical judgment.
when a condit ion related to the invest igational device ( for example, prefilled 
syringe) necessi tates m edical or surgi cal intervent ion to preclu de ei ther permanent 
impairment of a body  function or permanent damage to a body  structure, the 
serious outcom e of “requi red intervent ion” will be assigned.
Although all AEs after signing the ICF are recorded in the eCRF, SAE reporti ng begins after the 
patient has signed the ICF and has received investigational product.  However, if an SAE occurs 
after si gning the ICF, but prior to receiving investigational product, it needs to be reported 
ONLY if it is considered reasonably possibly related to study  procedu re.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 24 -
hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow-up SAE 
inform ation.
Pregnancy ( during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE. However, to fulfill regulatory requirements ,any pregnancy that occurs 
during the study , including those in which conceptio n occurred within 5 months after last 
administration of invest igational product, should be reported using the SAE process to collect
data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in patientsonce they  have 
discontinued and/or completed the study  (the patientsummary eCRF has been com pleted).  
However, if the invest igator lea rns of any  SAE, incl uding a death, at any  time after a patienthas 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
8.2.1.1. Suspec ted Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated detailed guidance or nati onal regulatory requi rements in parti cipat ing countries 
requi re the reporting of SUSARs . Lilly has procedures that will be fo llowed for the recording 
and expedited reporting of SUSARs that are consistent with glo bal regulat ions and the associated 
detailed guidance .
8.2.1.2. Adverse Event Monitoring with a Systematic Questionnaire
Suicidali ty will be assessed as requi red by the US Food and D rug Administration’s Divisio n of 
Neurol ogy for use in clinical trials invo lving all drugs for neurological indicat ions. Before 
administering the C-SSRS (Posner et al. 2011 ), study  site personnel  will quest ion the patient 
I5Q-MC-CGAG Clinical Protocol Page 36
LY2951742about any  change in the pre-exist ing condit ion(s) and the occurrence and nature of any AEs.  
Nonserious AEs obtained through the questionnaire are recorded and analyzed separately. Only 
serious AEs and AEs leading to discont inuat ion elici ted through the C -SSRS are to be recorded 
as AEs vi a eCRF. Serious adverse events must be reported to Lilly  or its designee wi thin 
24hours as SAEs.   Any suicidal behavior, or suicidal ideat ion per items 4 or 5 (active suicidal 
ideat ion with som e intent to act, ei ther wi thout specific pl an or wi th specifi c plan and intent) 
woul d prom pt ref erral of the pati ent to a m ental  health prof essional.
8.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product (or drug delivery  system such as a 
prefilled syringe ) so that the situation can be assessed.
8.3. Treatment of Overdose
No data are available at this stage of development.
8.4. Safety Assessments
8.4.1. Electrocardiograms
For each patient, a single, 12-lead digital ECG will be collected at the visits shown in the 
Schedule of Activities (Appendix 2 ). Electrocardi ogram s will have a central overread and 
shoul d be recorded according to th e study -specific recommendat ionsincluded in theECG
manual.   
Any clinically  significant findings from ECGs that result in a diagnosis should be reported to 
Lilly or i ts desi gnee as an AE viaeCRF.
8.4.2. Vital Signs
Vital signs will  include body  temperature, blood pressure, and pulse.  Blood pressure and pulse 
will be measured in triplicate in the sitt ing posit ion prior to bl ood draws and study drug 
administration (see Study  Schedule 
[Appendix 2]).
Any clinically  significant findings from vital signs measurement that result in a diagnosis should 
be reported to Lilly or its designee as an AE viaeCRF .
8.4.3. Laboratory Tests
For each patient, laboratory testsdetailed in Appendix 3 shoul d be conducted accordi ng to the 
Schedule of Activities (Appendix 2 )
. 
Any clinically  significant findings from laboratory tests that resul t in a di agnosis shoul d be 
reported to Lilly  or its designee as an AE via eCRF .
I5Q-MC-CGAG Clinical Protocol Page 37
LY2951742In addit ion, an immunogenicit y plasma sample will be collected, when possible, for any  patient 
who experiences a potential systemic allergic/hypersensit ivity react ion during the study  as 
judged by  the invest igator. This immunogenicit y plasma sample shoul d be co llected 
immediately  or as soon as possible, taking into consideration the availabilit y and wellbeing o f 
the pati ent. Exact date and time of the sample should be recorded on the laboratory requisit ion 
form.
8.4.4. Other Tests
Not applicable.
8.4.5. Safety Monitoring
Invest igators are responsible for monitoring in dividual  patient safety  throughout the tri al.If a 
study  patient/subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL 
≥2X ULN, clinical and laboratory  monitoring should be init iated by  the invest igator. Details for 
hepat ic monitoring de pend upon the severit y and persistence of observed laboratory  test 
abnorm alities.To ensure patient/subject safet y and com ply wit h regulatory  guidance, the 
investigator is to consult with the Lilly CRP/CRS regarding collect ion of specific reco mmended 
clinical informat ion and fo llow-up laboratory  tests. See Appendix 4 .
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
blinded methods. In addit ion, safet y data for the trial will also be reviewed periodically by  an 
independent Data Monitoring Co mmittee (DMC; an advisory  group for thi s study  formed to 
protect the integrit y of data; refer to Interim Analyses sec tion[Secti on 9.8]). In the event that 
safet y monitoring uncovers an issue that needs to be addressed by unblinding at the group level, 
members of the DMC can request additional analyses of the safet y data.
8.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities (Appendix 2 ), venous blood
samples of approximately 2.5 mL each will be collected to determine the serum concentrati ons 
of LY2951742.   A maximum o f 3samples m ay be collected at addi tional time points during the 
study  if warranted and agreed upon between both the investigator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by the sponsor.   
When a blood sample is collected , the time and date of l ast dose administration prior to blood 
sampling should be recorded .  The actual date and time (24-hour clock time )of each sampling 
will be recorded.   LY2951742 concentration informat ion that may/woul dunblind the study  will 
not be reported to invest igative sites or blinded personnel until the study has been unblinded .  
Bioanaly tical samples collected to m easure invest igational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study .
A validated assay will be used to determine serum LY 2951742 concentrations.  Samples will be 
analyzed at a laboratory  approved by  the sponsor.  
It is intended that blood samples co llected fro m patients who recei ved pl acebo should not be 
analyzed for determinat ion of serum concentrations of LY 2951742. 
I5Q - MC- CGAG  C l in ica l  P ro toco l Page  38
LY29517428 .6 .Pha rmacodynam ics
A t t h e  v i s i t s  a n d  t im e s  s p e c i f i e d  i n  t h e  S c h e d u l e  o f  A c t i v i t i e s  ( A p p e n d i x  2)
CC I,  v enou s  b lood  
s am p l e s  w i l l  b e  c o l l e c t e d  t o  d e t e rm i n e  t h e  pl a sm a  c o n c e n t r a t i o n s  o f  CGRP.   A  m ax im um  of  3
s amp l e s  m ay  b e  c o l l e c t e d  a t  a d d i t i o n a l  t im e  p oi n t s  du r ing  th e  s tudy  i f  w a r r a n t e d  a n d  a g r e e d  u p o n  
b e tw e e n  b o t h  t h e  i n v e s t i g a t o ra n d  s p o n s o r .   I n s t r u c t i o n s  f o r  t h e  c o l l e c t i o n  a n d  h a n d l i n g  o f  b l o o d  
s am p l e s  w i l l  b e  p r o v i d e d  b y  th e  spon so r .   W h e n  a  b l o o d  s am p l e  i s  co l l e c t ed ,  t h e  t im e  a n d  d a t e  o f  
l a s t  d o s e  a dm i n i s t r a t i o n  p r i o r  t o  b l o o d  s am p l i n g  s h o u l d  b e  r e c o r d e d .   T h e  a c t u a l  d a t e  a n d  t im e  
(2 4 - h o u r  c l o c k  t im e )o fe a c h  s am p l i n g  w i l l  b e  r e c o r d e d .
A  v a l i d a t e d  LY 2 9 5 1 7 4 2- to l e r an t  a s s a y  w i l l  b e  u s e d  t o  d e t e rm i n e  p l a sm a  CGRP  c o n c e n t r a t i o n s .   
S amp l e s  w i l l  b e  an a ly z ed  a t  a  l abo r a to ry  app rov ed  by  th e  spon so r .
P la sm a  CGRP  c o n c e n t r a t i o n  i n f o rm a t i o n  th a t  m ay /wou l d  unb l ind  th e  s tudy  w i l l  n o t  b e  r epo r t ed  
t o  i n v e s t i g a t i v e  s i t e s  o r  b l i n d e d  p e r s o n n e l  u n t i l  t h e  s t u d y  h a s  b e e n  unb l ind ed .   
B io an a ly t i c a l  s amp l e s  co l l e c t ed  to  m e a s u r e  CGRP  w i l l  b e  i d e n t i f i e d  b y  t h e  p a t i e n t  n um b e r  
( cod e d )  a n d  r e t a i n e d  f o r  a  m a x im um  of  1  y e a r  f o l l ow i n g  l a s t  p a t i e n t  v i s i t  f o r  t h e  s t u d y  a t  a  
f a c i l i t y  s e l e c t ed  by  th e  spon so r .
I5Q-MC-CGAG Clinical Protocol Page 39
LY29517428.8. Biomarkers
Blood samples for non -genet ic biomarker research will be co llected at the times specified in the 
Schedule of Act ivities (Appendix 2 ),where local regulat ions and ERBs allow.
Samples will  be used for research on the drug target, disease process, pathways associated with 
migraine headache and/or other pain condit ions, mechanism  of action of LY2951 742, and/or 
research method or in validat ing diagnost ic tools or assay(s) related to migraine headache and/or 
other pain condit ions.
All biomarker samples will be coded with the patient number.  These samples and any  data 
generated can be linked back to th e patientonly by the investigator site personnel.  Samples will 
be destroy ed according to a process consistent with local regulat ions.
Samples will  be retained for a m aximum  15 years after the l ast pati ent vi sit for the study , or f or a 
shorter period if l ocal regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.   This retent ion peri od enables use o f new techno logies, response to regulatory  
questions, and invest igation of variable response that may not be observed unt il later in drug 
development or when the drug is commercially available.
8.8.1. Samples for Immunogenicity Research
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testing will be 
collected to determine ant ibody  producti on against LY2951742 as specified in the Schedule of 
Activities (Appendix 2 )
.Immunogenicit y will be assessed by a validated assay designed to 
detect anti -drug ant ibodies in the presence o f the investigational product.  Ant ibodies may be 
further characterized and/or evaluated for their abilit y to neutralize the activit y of LY2951742 .
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit for the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.  The duration allows the sponsor to respond to future re gulatory  requests rela ted to 
LY2951742.
8.9. Health Economics
Health economic , disabili ty and qualit yof life assessments of LY2951742 in patients with 
migraine will be based on the fo llowing scales:
Migraine Disability Assessment test (M IDAS ): The MIDAS was designed to quantify 
headache-related di sabili ty over a 3 -month peri od.  Thi s instrum ent consists of five items that 
reflect the number of days reported as missing, or with reduced productivit y at work or hom e and 
social events ; a higher value is indicat ive of more disabilit y (Stewart 1999 ;Stewart 2001).  This 
instrum ent is considered highly  reliable and valid; and is correlated with clinical judgment 
regarding the need for medical care (Stewart 1999 ;Stewart 2001) . 
Migraine Specific Quality of Life questionnaire (MSQ v2.1): The MSQ v2.1 i s a self-
administered healt h status instrument, and was developed to address physical and emotional 
limitations of specific concern to individuals suffering fro m migraine headaches. The instrument 
consists of 14items that address 3 dom ains: (1) Role Functi on-Restrictive ;(2) Rol eFuncti on-
I5Q-MC-CGAG Clinical Protocol Page 40
LY2951742Preventive; and, (3) Em otional Function (Jhingran 1998). The instrument was designed with a 4-
week recall period, and is considered reliable, valid and sensit ive to change in migraine ( Jhingran 
1998; Rend as-Baum 2013). Clinically meaningful differences for each domain have been 
established and are widely used in the literature.
I5Q-MC-CGAG Clinical Protocol Page 41
LY29517429.Statistical Considerations and Data A nalysis
9.1. Determination of Sample Size
The study  will enroll approximately 825patients. Eligible pat ients will be randomized in 
blinded fashio nin a 2:1:1 ratio to placebo (target of 413 pat ients), LY2951742 120mg/month 
(target of 206 patients) , or 240mg/month (target of 206 pat ients).With the assumpt ion of a 26% 
discontinuat ion rate and an effect size o f 0.33, it is estimated that thissample size will provi de 
approximately  95% power that at l east 1 dose of LY2951742 will separate from placebo at a 
two-sided significance level of 0.05 based on simulat ions using Dunnett (Dunnett 1955) test.
Assumpt ions in the simulat ions werebased on data from two double -blind ,placebo -controlled ,
Phase 2 studi es, wi th adjust ment to reflect the longer treatm ent durati on and greater variabilit y 
expected in a larger, mult i-country  Phase 3 study .
Approximately  1557 pat ients may be screened to ensure randomizat ion of 825 patients, with an 
estimated 611 patients completing the study .  
9.2. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly or its des ignee.  Details o f 
statist ical analysis methods will be described in the statist ical analysis plan (SAP) document.
Unless otherwise specified, analyses will be conducted on an intent -to-treat (ITT) populat ion, 
which will include all pat ients who are random ized and receive at least one dose of 
investigat ional product .  Patients in the ITT population will be analyzed according to the 
treatm ent group to whi ch they  are randomized. When change fro m baseline is assessed, the 
patient will be included in the analy sis only  if he/she has a baseline and a postbaseline 
measurement.
The primary  analys is will be performed using a restri cted m aximumlikelihood -based mixed 
models repeated m easures (MMRM) technique (Secti on 9.4.1 ).   
Visitwise binary efficacy  variables will be analyzed using a generalized linear mixed model 
(GLIMMIX) as pseudo -likelihood -based mixed effects repeated measures analysis .
In addit ion to the MMRM approach, analysis o f covariance (ANCOVA) model or analysis of 
variance (ANOVA) with the l ast observat ion carried forward (LOCF) will also be implemented. 
When an ANCOVA model is used to analyze a cont inuous variable, the model will contain the 
main effects of treatment and region, as well as the conti nuous fixed covariates of baseline.   The 
ANOVA model will use the same terms except the continuous fixed covariate of baseline.  
TypeIII sum -of-squares for the l east-squares means will be used for th e stati stical co mpar isons.
Continuous efficacy and health outcome endpo ints will be analyzed using MMRM methods, as 
well as an ANCOVA model wit h LOCF imputation if deemed appropriate. 
Categorical co mpar isons between treatment groups will be performed usin g Cochran -Mantel -
Haenszel (CMH) controlling for region orusing the Fisher ’sexact test, where appropriate.
I5Q-MC-CGAG Clinical Protocol Page 42
LY2951742Patients will be pooled within each regi onfor statisti cal analysis purposes.   Region will be 
defined in the SAP.
All tests of treatment effects will be conducted at a 2-sided al pha level of 0.05, unless otherwise 
stated.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report.  Changes may only be made in the SAP prior to unblinding. 
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.
9.3. Treatment Group Comparability
9.3.1. Patient Disposition
The number and percentage of ITT patients who complete the study or discontinue early will be 
summariz ed for all  treatm ent groups for Study  Period III (double -blind treatment) and Study  
Period IV (post -treatm ent follow-up) both overall and by visit. 
Patient allocation by  invest igator will be summarized for Study Period III for all ITT patients. 
Patient allocation by  invest igator will also be listed for all study  periods.
9.3.2. Patient Characteristics
The fo llowing pati ent characteri stics at baseline will be summarized by  treatm entgroup for all 
ITT patients :
Dem ographic (age, gender, ethnic origin, height, weight, body mass index )
Migraine headache, headache ,variation of migraine/headache measures per 30 -
day baseline period.
Alcoho l
,tobacco , caffeine and nicotine consumption
Medical history  and pre-exist ing condit ion
Medical history and pre -exist ing condit ions will be summarized by preferred term within sys tem 
organ class (SOC) . 
9.3.3. Concomitant Therapy
The proporti on of  patients who received conco mitant medicat ion (as recorded viaeCRF )as well 
as abortive medicat ions (recorded through ePRO )will be summarized for all ITT patients for 
Study  Period III and Stud y Period IV separately.
9.3.4. Treatment Compliance
Not applicable.
I5Q-MC-CGAG Clinical Protocol Page 43
LY29517429.3.5. Electronic Patient -reported Outcome Diary Compliance
ePRO di ary com pliance at each period (including baseline, Month 1, 2, 3, … till Month 10) will 
be calculated.  Diary  com pliance at each period is calculated as:
Actual  number  of diary  days  in the  period
Expected  number  of diary  days  in the  period∗100
Actu al number of di ary days is calculated as the total number of days wit h non -missing answers. 
9.4. Primary  and Secondar y Anal yses
9.4.1. Primary Analyses
The primary  efficacy  measure is the overall mean change from the baseline period in the number 
of monthly migraine headache day sduring the 6-month double -blind treatm ent phase , and t he 
primary  analysis will evaluate the efficacy of LY2951742 (120 or 240 mg/month)compared wi th 
placebo . 
The primary  analys iswill be performed using a restricted maximum likelihood -based mixed 
models repeated m easures technique.  The analysis will include the fixed categorical effects of 
treatm ent, region , month, and treatm ent-by-month interact ion, as well as the continuous fix ed 
covari ates of baseline number of migraine headache day s and baseline number of migraine 
headache days -by-monthinteracti on.  
An unstructured covariance structure will be used to model wit hin-patient errors. The Kenward -
Roger (Kenward and Roger 1997) a pproximat ion will be used to estimate deno minator degrees 
of freedo m. If the model does not converge with both the Hessian and the G matrix being 
positive definite under the default fitting algorithm used by PROC MIXED, the Fisher scoring 
algorithm will be implemented by  specifying the SCORING option in SAS. If the model st ill 
fails to converge, the model will be fit using covariance matrices o f the following order specified 
by a decreasing number of covariance parameters unt il convergence is met: 
Hetero geneous Toeplitz 
Heterogeneous First -order autoregressive 
Toeplitz 
First-order autoregressive 
When the unstructured covariance matrix is not utilized, the sandwich estimator (Diggle and 
Kenward 1994) will be used to estimate the standard errors of the fixed effects parameters.  The 
sandwich est imator is implemented by specifying the EMPIRICAL option in SAS®.  When the 
sandwich est imator is utilized, the Kenward -Roger approximat ion for denominator degrees of 
freedo m cannot be used.  Instead, the deno mina tor degrees of freedom will be partit ioned into 
between -subject and within -subject portions by  the DDFM=BETWITHIN option in SAS®.  
SAS®PROC MIXED will be used to perform the analysis.
I5Q-MC-CGAG Clinical Protocol Page 44
LY29517429.4.2. Key Secondary Analyses
The key  secondary  object ives (see Table CGAG. 1) will be tested using a nappropri ate m ultiple 
testing approach providing strong control of the familywise error rate (for the primary and key 
secondary  tests) at a one -sided 0.025 alpha level (or, equivalent ly, two -sided 0.05 alpha level).  
Details o f the specific testing methodology  (including testing order, relationship and t ype I error 
allocat ionand propagati on)will be specified in the SAP.  
The key  secondary  measures will be analyzed for the double- blind treatment ( Study Period 
III).
For the conti nuous key secondary  measures, the change fro m baseline during the 6 -month
doubl e-blind treatment phase will be analyzed from repeated measur es analyses .For the analysis 
of 50% , 75%, and 100% response, the percentage of patients meet ing response criteria during the 
6-month double -blind treatment phase will be est imated for each treatment fro m a categori cal, 
pseudo -likelihood -based repeated measures analysis of lo ngitudinal binary  outcom es indicating 
whether patients meet response criteria. This analysis will be implemented using the GLIMMIX 
procedure in SAS .
9.4.3. Other Secondary and Tertiary Efficacy Analyses
Theother secondary  and exploratory  efficacy analyses will be conducted for the doubl e
-blind 
treatm ent phase, and for the double -blind treatment and post -treatm ent follow-up phases ( Study 
Period III and Study Period IV )combined.   Further details regarding other secondary  and terti ary 
effica cy analyses are summarized in the SAP.
9.5. Safety Analyses
The safet y analys es will  be conducted for the double- blind treatment and post -treatm ent follow-
up phases, as well as the two peri odscombined.  For the two phases combined, only repeated 
measures and t ime-to-event analys es will  be conducted.
The safet y and tol erabilit y of treatm ent will be assessed by  summarizing the following:
adverse events
otreatm ent-emergent adverse events ( TEAEs )
by preferred term
by SOC
by maximum severit y 
by outcom e
considered to be rel ated to investigat ional product by  invest igator
oserious adverse event
oadverse event leading to discont inuat ion
Suicidal  ideati on and behavi ors assessed by solicit ed questioning using the C-
SSRS
I5Q-MC-CGAG Clinical Protocol Page 45
LY2951742Vital signs and weight
electrocardi ogram s
Laboratory  measurements
Anti-LY2951742 ant ibody
9.5.1.1. Categorical Safety Variables
Unless specified otherwise, the categorical safet y analyses will include both schedule and 
unscheduled visits.
Com parisons between treatment groups for all categorical safet y measures will be made using 
the Fisher ’sexact test for S tudy Period III (double -blind treatment) withtheITT populat ion.  
Descript ive statistics only will be presented for the treatment groups in the post -treatm ent 
follow-up phase ( Study Period IV )with the post-treatment popul ation.
9.5.1.2. Adverse Events
Treatment -emergent adverse events are defined as the reported AEs that first occurred or 
worsened during the postbaseline phase co mpared with baseline phase.  For each TEAE, the 
severit y level o f the event (mild, moderate, o r severe) will be determined by pat ient or physician 
opinio n.  The Medi cal Dict ionary for Regul atory  Activities(MedDRA ) Lowest Level Term will 
be used in the treatment -emergent computation.  For each Lowest Level Term , the m aximum  
severit y at baseline wil l be used as the baseline severit y.  If the maximum severit y during 
postbaseline is greater than the maximum baseline severit y, the event is considered to be 
treatm ent-emergent for the specific postbaseline period.  For each patient and TEAE, the 
maximum s everi ty for the MedDRA l evel being displayed (Preferred Term, High Level Term, or 
SOC )is the maximum postbaseline severit y observed from  all associ ated L owest Level Terms
mapping to that MedDRA level.  
For events that are gender -specific, the deno minator and computation of the percentage will 
include only  patients from the given gender.
9.5.1.3. Suicide -Related Thoughts and Behaviors
Suicidal  ideati on, suicidal  behavi or, and non -suicidal  self-injuri ous behavi orbased on the 
C-SSRS will be summarized by treatment group.  For each of the fo llowing events, the number 
and percentage of patients with the event will be enumerated by  treatm ent:  com pleted sui cide, 
non-fatal suicide attem pt, interrupted attempt, aborted attempt, preparatory  acts or behavior, 
active suicida l ideat ion with specific plan and intent, active suicidal ideat ion with som e intent to 
act wi thout specific plan, active suicidal ideat ion with any methods (not pl an) wi thout intent to 
act, non -specific act ive suicidal thoughts, wish to be dead, and non -suicidal self -injuri ous 
behavior.   
In addition, the number and percentage of patients w ho experienced at least one of the
composite measures during Study  Period III and Study  Period IV separately will be presented
and co mpared .  These include suicidal acts (com pleted sui cide and nonfatal suicidal attempts), 
suicidal behavi or (suici dal acts, interrupted attem pts, aborted attem pts, and preparatory  acts or 
behavior), treatment -emergent sui cidal  ideati on or treatm ent-emergent suicidal behavior.
The Fisher’s exac t test will be used for treatment comparisons.
I5Q - MC- CGAG  C l in ica l  P ro toco l Page  46
LY29517429 .5 .1 .4 .V i ta l  S igns  and  We igh t
V it a l  s ign s  co l l e c t ed  du r ing  th e  s tudy  i n c l u d e  s y s t o l i c  a n d  d i a s t o l i c  b l o o d  p r e s s u r e ,  p u l s e ,  a n d  
t em p e r a tu r e .   B l ood  p r e s su r e  and  pu l s e  m e a s u r em e n t s  w i l l  b e  t a k e n  w h e n  t h e  p a t i e n t i s  i n  a  
s i t t ing  po s i t i on .  T h r e e  m e a s u r em e n t s  o f  s i t t i n g  b l oo d  p r e s s u r e  a n d  p u l s e  w i l l  b e  c o l l e c t e d  a t  
e v e r y  v i s i t ;  t h e3  s i t t i n g  b l o o d  p r e s s u r e  a n d  p u l s e  m e a s u r em e n t s  w i l l  b e  a v e r a g e d  a n d  u s e d  a s  t h e  
v a l u e  f o r  t h a t  v i s i tf o r  a n a l y s i s .  
T h e  i n c i d e n c e  r a t e s  o f  p a t i e n t s  w i t h  t r e a tm e n t - em e rg en t  v i t a l  s ign  and  w e i gh t  ch ang e s  b a s ed  a t  
a n y  t im e  p o s t b a s e l i n e  a n d  a t  LOCF  e n d p o i n t  w i l l  b e  a s s e s s e d  u s i n g  th e  F i s h e r ’ s  e x a c t  t e s t .   
S p e c i f i c  c r i t e r i a  f o r  t r e a tm e n t  em e r g e n t  d e f i n i ti o n  w i l l  b e  d o c um e n t e d  i n  t h e  SAP .
9 .5 .1 .5 .E lec t roca rd iog ram  In te rva ls  and  Hea r t  Ra te
A n a l y s e s  o f  c o r r e c t e d  QT  i n t e r v a l  w i l l  b e  c a l c u l a t e d  u s i n g  tw o  c o r r e c t i o n  f o rm u l a s .   T h e  QT cF  
(m e a s u r e d  i n  m i l l i s e c o n d s  [m s e c ] )  w i l l  b e  c a l c u l a t e d  w i t h  F r i d e r i c i a ’ s  f o rm u l a  a s  QT /RR⅓.   Th e  
L a r g e  C l i n i c a l  T r i a l  P o pu l a t i o n  B a s e d  QT  C o r r e c t i o n  (QT cLCTPB )  (m s e c )  w i l l  b e  c a l c u l a t e d  
w ith  th e  f o rm u l a  a s  QT /RR0 .413.   T h e  n um b e r  a n d  p e r c e n t  o f  p a t i e n t s  m e e t i n g  c r i t e r i a  f o r  
t r e a tm e n t - em e r g e n t  a b n o rm a l i t i e s  i n  ECG  i n t e r v a l s  ( pu l s e  r a t e  [ PR] ,  QRS ,  QT cF ,  a n d  
QT cLCTPB )  a n d  h e a r tr a t e  a t  any  t im e  du r ing  s tudy  w i l l  b e  s umm a r i z e d .   T r e a tm e n t  g r o u p  
com p a r i s o n s  w i l l  b e  p e r f o rm e d  u s i n g  th e  F i sh e r ’ s  ex a c t  t e s t .   
9 .5 .1 .6 .Labo ra to ry  Tes ts
CC IT h e  i n c i d e n c e  r a t e s  o f  p a t i e n t s  w i t h  t r e a tm e n t- em e rg en t  abno rm a l ,  h igh ,  o r  l ow  l abo r a to ry  v a l u e s  
a t  any  t im ep o s t b a s e l i n e  a n d  a t  LOCF  e n d p oi n t  w i l l  b e  a s s e s s e d  u s i n g  th e  F i sh e r ’ s  ex a c t  t e s t  fo r  
e a ch  l abo r a to ry  t e s t .
P a t ien t s  w i l l  b e  d e f i n e d  a s  h a v i n g  a  t r e a tm e n t - em e rg en t  l ow  v a lu e  i f  th ey  h av e  a l l  n o rm a l  o r  h igh  
v a l u e s  a t  b a s e l i n e ,  f ol l o w ed  by a  v a lu e  b e l ow  th e  l ow e r  r e f e r e n c e  l im i t  a t  a n y  p o s t b a s e l i n e  v i s i t .   
P a t ien t s  w i th  a l l  no rm a l  o r  h i g h  v a l u e s  a t  b a s e l i n e  ( n o  l ow  v a l u e s )  w i l l  b e  i n c l u d e d  i n  t h e  
a n a l y s i s  o f  t r e a tm e n t - em e r g e n t  l ow  l a b o r a t o r y  v a l u e s .   P a t i e n t s  w i l l  b e  d e f i n e d  a s  h a v i n g  a  
t r e a tm e n t - em e r g e n t  h i g h  v a l u e  i f  t h e y  h a v e  a l l  n o rm a l  o r  l ow  v a l u e s  a t  b a s e l i n e ,  f ol l o w ed  by a  
v a l u e  a b o v e  t h e  u p p e r  r e f e r e n c e  l im i t  a t  a n y  po s tb a s e l in e  v i s i t .   P a t i en t s  w i th  a l l  n o rm a l  o r  l ow  
v a l u e s  a t  b a s e l i n e  ( n o  h i g h  v a l u e s )  w i l l  b e  i n c l u d e d  i n  t h e  a n a l y s i s  of  t r e a tm e n t - em e rg en t  h i g h  
l abo r a to ry  v a lu e s .
F o r  a n a l y t e s  s im p l y  c l a s s i f i e d  a s  n o rm a l  o r  a b n o rm a l ,  p a t i e n t s  w i l l  b e  d e f i n e d  a s  h a v i n g  a  
t r e a tm e n t - em e r g e n t  a b n o rm a l  v a l u e  i f  t h e y  h a v e  a l l  n o rm a l  v a l u e s  a t  b a s e l i n e ,  f ol l o w e d  b y  a n  
abno rm a l  v a lu e  a t  any  p o s t b a s e l i n e  v i s i t .  P a t i e n t s  w i t h  a l l  n o rm a l  v a l u e s  a t  b a s e l i n e  w i l l  b e  
i n c l u d e d  i n  t h e  a n a l y s i s  o f  t r e a tm e n t - em e rg en t  abno rm a l  l abo r a to ry  v a l u e s .
 
 
 
 
I5Q - MC- CGAG  C l in ica l  P ro toco l Page  47
LY2951742 
.
9 .7 .O the r  Ana lyses
9 .7 .1 .Hea l th  Econom ics
T h e  c h a n g e  f r om  b a s e l i n e  t o  e a c h  p o s t b a s e l i n e  v i s i t  f o r  th e  doub l e - b l ind  t r e a tm e n t  p h a s e  a n d  f o r  
th e  d o u b l e - b l i n d  t r e a tm e n t  a n d  p o s t- t r e a tm en t  f o l l o w -u p  p h a s e s  c om b i n e df o r  MSQ  v 2 .1( R ol e  
F u n c ti o n -R e s t r ic t i v e ,  R o l e  F u n c t i o n -P r e v e n ti v e ,  Emo t i on a l  F u n c ti o n ,a n dto t a l  s co r e )a n d
M IDAS( i t em  s co r e s  and  to t a l  s co r e )w i l l  b e  a n a l y z e d .   I n  a d d i ti o n ,  c a t e g o r i c a l  a n a l y s i s  f o r  t h e  
f r e q u e n c y  m e a su r e  w i l l  b e  p e r fo rm ed .
9 .7 .2 .Subg roup  Ana lysesCC I
S u b g r o u p  a n a l y s e s  w i l l  b e  p e r f o rm e d  f o r  th e  p r im a rye f f i c a c y  m ea su r e  ( ch ang e  f rom  b a s e l i n e  i n  
th e  n um b e r  o f  m i g r a i n e  h e a d a c h e  d a y s )  o n l y  f or  th e  ITT  p a t i e n t s  i n  S tudy P e r i od  I I I.
I5Q-MC-CGAG Clinical Protocol Page 48
LY2951742Table CGA G.3. Definition of Subgroup Variables
Subgroup Variable Categories
Sex Male, female
Racial Origin (combine those with 
less than 10%)American Indian / Alaskan Native
Asian
Black / African American
Native Hawaiian / Pacific Islander
White
Multiple
Ethnicity Hispanic o r Latino
Not Hispanic or Latino
Region Defined in the statistical analysis plan (SAP)
Baseline number of migraine 
headache days2levels of baseline migraine frequency :
<8 migraine headache days
≥8 migraine headache days
Treatment -resistant status Treatment -resistant status about whether a patient has failed 2 or 
more prophylactic treatments (Yes or No)
Having aura or not (during baseline 
period)Yes or No
Baseline a nti-drug antibody status Any confirmed positive anti-drug antibody at baseline (Yes vs 
No)
Neutralizing anti-drug antibody
statusAny positive neutralizing anti-drugantibody time point (Yes 
versus No) –note that neutralizing anti-drug antibody assay s are 
performed only on confirmed-positive anti-drug antibod ies s.
Treatment -emergent anti-drug 
antibody statusAny treatment -emergent anti-drug antibody (Yes v ersus No)
9.8. Interim Analyses
Two interim analyses are antici pated for this study.  The first possible interim analysis will  
occur during Study  Period III (double -blind treatment) and could result in stopping or modifying 
the trial for saf ety or fut ilityreasons .  Details will be documented in the Statistical Analysis 
Center SAP and the DMC Charter.  A DMC will be convened to assess safet y and fut ility 
analys es.  Only the DMC is authorized to evaluate unblinded interim efficacy and safet y 
analyses.  Study  sites will receive information about interim results ONLY if they  need to know 
for the safet y of their patients.
The second interim analysis will be conducted after all pat ients have had the opportunit y to 
complete Study  Period III, and thus, will be the final analy sis of the primary efficacy  endpoint.
Unblinding details are specified in the unblinding plan sect ion of the SAP or a separate 
unblinding plan document .
Addit ional interim analyses m ay be conducted in support of regulatory  submissio ns if necessary .
I5Q-MC-CGAG Clinical Protocol Page 49
LY295174210.Study  Governance Considerations
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process
10.1.1. Informed Consen t
The invest igator is responsible for ensuring:
that the patientunderstands the potential risks and benefits of part icipating in the 
study
that informed consent is given by each patient.  This includes obtaining the 
appropriate signatures and dates on the ICF prior to the performance of any 
protocol  procedures and prior to the administration of invest igational product.
answering any quest ions the pati entmay have throughout the study  and sharing in 
a timely manner any  new informat ion that m ay be rel evant to the patient’s
willingness to continue his or her participat ion in the trial.
10.1.2. Ethical Review
The invest igator must give assurance that t he ERB was properly const ituted and convened as 
requi red by Internat ional Conference on Harmonisation (ICH) guidelines and other applicable 
laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs
must be compliant with the ICH guideline on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
inform ed consent docum ent
relevant curri cula vi tae
10.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
applicable ICH GCP guideline s
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party organi zation (TPO) .
I5Q-MC-CGAG Clinical Protocol Page 50
LY295174210.1.4. Investigator Information
Invest igators in this clinical trial should be n eurol ogists, headache specialists, or other special ists
with experi ence in headache clinical trials and treating migraine headache pat ients.
10.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  descri bes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
10.1.6. Final Report Signature
Theclinical study  report ( CSR)coordinating investigator will sign the final CSR for this study , 
indicat ing agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
An invest igator selected by  the study  team  will serve as the CSR coordinat ing invest igator.  If 
this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by Lilly to 
serve as the CSR coordi nating invest igator.
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
10.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its repr esentatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instructi on on the protocol, the complet ion of the eCRFs, and 
study  procedures .
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail/e-mail, telephone, and/or fax
review and evaluate eCRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives willperiodically check a sample of the patient data
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or its 
representatives ,and/or by regul atory  agencies at any  time.  Invest igators will be given notice 
before an audit occurs.
I5Q-MC-CGAG Clinical Protocol Page 51
LY2951742To ensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable
data, the invest igator will ke ep records of ECGs, laboratory  tests, clinical notes, and patient
medical records in the patient files as original source documents for the study  according to 
retenti on requi rements as outlined by the ICH guidelines. If requested, the invest igator will 
provide the sponsor, applicable regulatory agencies, and applicable ERBs with direct access to 
original  source docum ents.
10.2.1. Data Capture System
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data ente red by  the si te into the sponsor -provided electronic data capture system.
Some or all  of a patient’s data will be direct ly entered into the eCRF at the time the i nformation 
is obtained. In instances where direct data ent ry is not used, the site will main tain source 
docum entati on in the tri al files ,and the patient’s data will  be transcribed into the eCRF. Any 
data for whi ch the eCRF will serve as the source document, or any  other data not entered direct ly 
into the eCRF, will be identified and documented by the site in the site ’s trial  file. For data 
handled by  a data m anagement TPO, eCRF data and some or all data that are related will be 
managed and stored electronically in the TPO system. Subsequent to the final database lock, 
validated data will be tra nsferred to the sponsor. For data handled internally, eCRF data and 
some or all data that are related will be managed by the sponsor and stored electronically in the 
sponsor ’s system .
In thi s study , pati ent migraine headache data will be collected directl y via an ePRO diary as part 
of an ePRO/Clinical Outcome Assessment (COA) system. Patient -rated scales/quest ionnaires 
will be co llected direct ly via an ePRO tablet device at each visit. Data entered into the 
ePRO/COA system will serve as the source data.
If ePRO/COA records are stored at a third -party  site, investigator sites will have continuous 
access to the source documents during the study  and will receive an archival copy  at the end of 
the study  for retenti on.
Any data for which the ePRO/COA instrumen t record will serve to collect source data will be 
ident ified and documented by each site in that site’s study file.
Case report form data will be encoded and stored in a clinical trial database.   
Data m anaged by  a central  vendor, such as laboratory  test data or ECG data, will be stored 
electroni cally in the central vendor’s database syst em.  Data will subsequent ly be transferred 
from the central  vendor to the Lilly data warehouse . Data from complaint forms submitted to 
Lilly will be encoded and stored i n the gl obal product com plaint m anagement system .
I5Q-MC-CGAG Clinical Protocol Page 52
LY295174210.3. Study and Site Closure
10.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , theinvest igator, or the ERB 
of the study  sitejudges it necessary for medical , safety, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
10.3.2. Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I5Q-MC-CGAG Clinical Protocol Page 53
LY295174211.References
Diggle P, Kenward MG. Informative drop -out in longi tudinal  data analysis. J Royal Statist Soc 
Series C: Appl Statist . 1994;43(1):49 -93.
Dunnett CW. A mult iple co mpar ison procedure for comparing several treatments with a control. 
J Am Stat Assoc . 1955;50(272):1096 –1121.
Goadsby  PJ, Edvinsson L. The tri gemino vascular system and migraine: Studies characterizing 
cerebrovascul ar and neuropeptide changes seen in humans and cats. Ann Neurol . 
1993;33(1):48 -56.
Goadsby  PJ, Edvinsson L, Ekm an R. Vasoactive peptide release in the extracerebral circulat ion 
of humans during migraine headache. Ann Neurol . 1990;28(2):183 -187.
Guy W. ECDE U assessment manual for psychopharmaco logy, revised 1976. Rockville, MD: 
National Inst itute of Mental Health, Psychopharmacology  Research Branch. p 217 -222. 
Available at: https://archive.org/details/ecdeuassessmentm1933guyw. Accessed 27 July 2015 .
[ICHD -
3]Headache Classificat ion Co mmittee of the Internat ional Headache Societ y (IHS). The 
International Classificat ion of Headache Disorders, 3rd edit ion (beta versio n). Cephalalgia. 
2013;33(9):629 -808.
Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validat ion of 
the Migraine -Specific Qualit y of Life Quest ionnaire. Headache .1998;38(4):295 -302.
Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum 
likelihood. Biometrics . 1997;53(3) :983-997.
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a 
causat ive role in migraine. Cephalalgia
.2002;22(1):54 -61.
Lassen LH, Jacobsen VB, Pedersen PA, Sperling B, Iversen H, Olesen J. Human calcitonin gene -
related pepti de (hCGRP) -induced headache in migraineurs. Eur J Neurol . 
1998;5(suppl 3):S63.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin 
GA, Greenhill L, Shen S, Mann JJ. The Co lumbia -Suicide Severi ty Rating Scale: init ial 
validit y and internal consistency findings from three mult isite studies wit h adolescents and 
adults.Am J Psychiatry . 2011;168(12):1266 -1277.
Rendas -Baum R, Bl oudek LM, Maglinte GA, Varon SF. The psy chometric properti es of the 
Migraine -Specific Qualit yof Life Quest ionnaire version 2.1 (MSQ) in chronic migraine
patients . 
Qual Life Res .2013;22 (5):1123 –1133 .
Rizzoli P. Preventive pharmacotherapy  in migraine. Headache . 2014;54(2):364 -369.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidenc e-based 
guideline update: Pharmaco logic treatm ent for epi sodic migraine prevent ion in adults: Report 
of the Qualit y Standards Subcommittee of the American Academy of Neurology  and the 
American Headache Societ y. Neurology .2012;78(17):1337 -1345.
I5Q-MC-CGAG Clinical Protocol Page 54
LY2951742Stewart WF ,Lipton RB, Dowson AJ, Sawyer J . Development and testing of the Migraine 
Disabili ty Assessment (MIDAS) Questionnaire to assess headache -related di sabili ty (abstract). 
Neurology 2001;56 (6 Suppl 1) :S20–S28.
Stewart WF , Lipton RB, Kol odner K, Liberman J, Saw yer J. Reliabilit y of the migraine 
disabili ty assessment score in a populat ion-based sample of headache sufferers. Cephalalgia
1999; 19(2):107 -114.
Villaló n CM, Olesen J. The role of CGRP in the pathophysio logy of migraine and efficacy  of 
CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther . 
2009;124(3):309 -
323.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with 
disabili ty (YLDs) for 1160 sequelae of 289 diseases and injuries 1990 -2010: a systemat ic 
analysis for the Global Burden of Disease Study  2010. Lancet .2012;380(9859): 2163 -2196.
I5Q-MC-CGAG Clinical Protocol Page 55
LY2951742Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
complaint A complaint is any written, ele ctronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
CRP/CRS Lilly  Clinical Research Physician/Clinical Research Scientist
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or
through their legally acceptable representatives .
ePRO electronic patient -reported outcomes
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial , incl uding products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the auth orized form.
ITT intent to treat : The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating o n the basis of the intention to treat a patient (that is, the planned 
treatment regimen) rather than the actual treatme nt given.  It has the consequence that 
patients allocated to a treatment group should be followed up, assessed ,and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IWRS interactive web-response sy stem
SAE serious adverse event
TEAE treatment -emergent adverse event : Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and thatdoes not necessarily have to 
have a causal relationship with this treatment .
I5Q-MC-CGAG Clinical Protocol Page 56
LY2951742Appendix 2. Schedule of A ctivities
I5Q-MC-CGAG Clinical Protocol Page 57
LY2951742Schedule of Activities , Protocol I5Q-MC-CGAG
Study Period (SP)SP I-
ScreeningSP II -
Prospective 
BaselineSP III -Treatment SP IV –Follow -up
(Target) I nterval (days) 
since previous visit30-45 14 16 30 30 30 15 15 15 15 60 60
ETAllowable range (days) 
between visits3-45 30-40 a
Interval allowance (days) +/- 1 +/- 3 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 5 +/- 5
Visit 1 2 3 4 b 5 6 7 8 9c10 11c12 13 14
Month 0 0.5 1 2 3 4 4.5 5 5.5 6 8 10
Assessments and Procedures
Informed consent X
Inclusion /exclusion X X X
Demographics X
Physical examination d X
Height X
Weight X X X X
Waist and hip 
circumference X
Medical history X
Pre-specified 
migraine historyX
I5Q-MC-CGAG Clinical Protocol Page 58
LY2951742Visit 1 2 3 4b5 6 7 8 9c10 11c12 13 14ET
Month 0 0.5 1 2 3 4 4.5 5 5.5 6 8 10
Substance use X
ECG e X X X X X
Vital signs f X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X
ePRO training X
ePRO daily patient entries X X X X X X X X X X X X X X
Patient training video X
Clinical Laboratory Tests and Sampling Schedules
Hematology X X X X X X
Clinical chemistry X Xg Xg Xg Xg Xg
HDL X Xg Xg Xg Xg Xg
HbA1c X X X X
Fasting insulin/
fasting C -peptideXgXgXg
UrinalysishX X X X X
Serum Pregnancy (for 
women of childbearing 
potential) or FSH at Visit 
1 (all other female 
patients) iX X X X
Urine pregnancy i X X X X X X
Urine drug screen X
I5Q - MC- CGAG  C l in ica lP ro toco l Page  59
LY2951742V i s i t 1 2  3  4b5  6  7  8  9c1 0  1 1c1 2  1 3  1 4ET
M on th 0 0 .5 1  2  3  4 4 .5 5 5 .5 6  8  1 0
Imm u n o g e n i c i t yjX  X  X  X  X X X  X
B i om a r k e r  st o r a g e  s am p l ejX X  X XX X X  X
PK  b l o o d  s am p l ejX  X  X  X  X  X  X  X  X  X  X  X
RNA X X X
S t u d y  d r u g  a dm i n i s t e r e dkXX  X  X  X X
S c a l e s ,  Qu e s t i onn a i r e s ,  and  Ou t c om e  M e a su r e s
M IDAS X X X X  X
MSQv 2 . 1 XX  X  X  X XX X  X
N o n- m i g r a i n e  c h r o n i c  
p a i n  a s s e s sm e n tlX X X X
PG I-S XX  X  X  X XX X  X
PG I- I X  X  X  X XX X
C -SSRS /SHSF ,  SHFU mX X  X X  X  X  X XX  X  X  XCC I
Ab b r e v i a t i o n s :   AE  =  a d v e r s e  e v e n t ;  CGRP  =  C a l c i t o n i n- g e n e  r e l a t e d  p e p t i d e ;  C -SSRS  =  C o l um b i a- S u i c i d e  S e v e r i t y  R a t i n g  S c a l e;  ECG  =  e l e c t r o c a r d i o g r am ;  
ePRO  =  e l e c t r o n i c  p a t i e n t  r e p o r t e d  o u t c om e s ;  ET  =  e a r ly  t e rm i n a t i o n ;  FSH  =  f o l l i c l e  s t im u l a t i n g  h o rm o n e ;  HDL  =  H i g h- d en s i ty  l i p o p r o t e i n ;  M IDAS  =  
M i g r a i n e  D i s a b i l i t y  A s s e s sm e n t  t e s t ;MSQ( v 2 . 1 )=  M i g r a i n e  S p e c i f i c  Q u a l i t y  o f  L i f e  Q u e s t i o n n a i r e ;  PG I- I  =  P a t i e n t  G l o b a l  Im p r e s s i o n  o f  Im p r o v em e n t ;  
PG I- S  =  P a t i e n t  G l o b a l  Im p r e s s i o n  o f  S e v e r i t y ;  PK  =  p h a rm a c o k i n e t i c s;RNA  =  r i b o n u c l e i c  a c i d ;  SHSF  =  S e l f- h a rm  s u p p l em e n t  f o rm ;  SHFU  =  S e l f- h a rm  
f o l l ow - u p  f o rm.
N o t e :  Se l e c t e d  t e s t s  m a y  b e  o b t a i n e d  i n  t h e  e v e n t  o f  a  t r e a tm e n t - em e r g e n t  h e p a t i c  a b n o rm a l i t y  a n d  m a y  b e  r e q u i r e d  i n  f o l l ow - u p  w i t h  p a t i e n t s  i n  c o n s u l t a t i o n  
w i t h  t h e  L i l l y ,  o r  i t s  d e s i g n e e ,  c l i n i c a l  r e s e a r c h  p h y s i c i a n .  S e e  Ap p e n d i x  4f o r  mo r e  d e t a i l s  r e g a r d i n g  s p e c i f i c  h e p a t i c  m o n i t o r i n g  t e s t s .   I f  t h e  p a t i e n t  h a s  
d i s c o n t i n u e d  t h e  t r i a l  a n d  r e t u r n s  f o r  h e p a t i c  f o l l ow - u p ,  t h e  s i t e  s h o u l d  u s e  t h e  8 0 0  s e r i e s  a s  t h e  v i s i t  d e s i g n a t i o n .CC I
I5Q - MC- CGAG  C l in ica lP ro toco l Page  60
LY2951742S ch edu l e  o f  A c t i v i t i e s,  P r o t o c o lI 5Q - MC- CGAG  ( f o o tn o t e s )
aT h e  e l i g i b i l i t y  p e r i od  o f  t h e  p r o s p e c t i v e  b a s e l i n e  a s s e s sm e n t  w i l l  l a s tf r om  3 0  t o  4 0  d a y s .  I n v e s t i g a t o r s  a n d  p a t i e n t s  m a y  h a v e  u p  t o  a n  a d d i t i o n a l  5d a y s  t o  
s c h e d u l e  t h e i r  V i s i t  3  a p p o i n tm e n t  ( b e y o n d  t h e4 0  d a y s ) ;  h ow e v e r ,  e l i g i b i l i t y  w i l l  b e  b a s e d  o n  t h e  3 0 - 4 0  d a y  p e r i o d .
bV i s i t  i s  t o  i n c l u d e  a  r e v i ew  o f  a n y  s p o n t a n e o u s l y  r e p o r t e d  a d v e r s e  e v e n t s  a n d  c o l l e c t i o n  o f  b l o o d  s am p l e s  f o r  imm u n o g e n i c i t y ,PK ,  a n d  CGRP  p l a sm a.
cV i s i t  9  a n d  V i s i t  1 1  a r e  l a b o r a t o r y  v i s i t s  ( f o r  PK  a n d  CGRP  p l a sm a )  on ly .  A d v e r s e  e v e n t s  a r e  n o t  i n t e n d e d  t o  b e  c o l l e c t e d  a t  t h e s e  v i s i t s  b e c a u s e  p a t i e n t s  m a y  
b e  g o i n g  t o  a  d i f f e r e n t  l o c a t i o n  f o r  l a b o r a t o r y  a s s e s sm e n t s .   H ow e v e r ,  a n y  s p o n t a n e o u s l yr epo r t e dAEs  a t  t h e s el a b  v i s i t s  s h o u l d  b e  r e p o r t e d  o n  t h e  AE  p a g e .
dPhys i c a l  e x am i n a t i o n s  a t  s c r e e n i n g  m u s t  i n c l u d e  a  n e u r o l o g i c a l  e x am .
eE l e c t r o c a r d i o g r am s  (ECGs )w i l l  b e  p e r f o rm e d  a t  V i s i t  1 ,  V i s i t  3 ,  V i s i t  1 2 ,  a n d  V i s i t  1 4o r  e a r l y  t e rm i n a t i o n .   N o t e :  Th e  V i s i t  3  ECG  s h o u l d  b e  c o l l e c t e d  p r i o r  
t o  b l o o d  d r aw s  a n d  d o s i n g .   P a t i e n t s  m u s t  b e  s u p i n e  f o r  a p p r o x im a t e l y  5  t o  1 0  m i n u t e s  b e f o r e  ECG  c o l l e c t i o n  a n d  r em a i n  s u p i n e  b u t  aw a k e  d u r i n g  ECG  
c o l l e c t i o n .  
fV i t a l  s i g n s  w i l l  i n c l u d e  b o d y  t em p e r a t u r e ,  b l o o d  p r e s s u r e ,  a n d  p u l s e .   B l o o d  p r e s s u r e  a n d  p u l s e  w i l l  b e  m e a s u r e d  i n  t r i p l i c a t e  i n  th e  s i t t i n g  p o s i t i o n  a n d  s h o u l d  
b e  m e a s u r e d  p r i o r  t o  b l o o d  d r aw s .   B l o o d  p r e s s u r e  w i l l  b e  a s s e s s e d  b y  u t i l i z i n g  a  c a l i b r a t e d  m a c h i n e .
gC h em i s t r y  s am p l e sc o l l e c t e d  a t  V i s i t  3 ,  V i s i t  7 ,  V i s i t  1 2 ,  and  V i s i t  14  or  e a r ly  t e rm in a t io nm u s t  b e  f a s t i n g .  F a s t i n g  i sd e f i n e d  a s  n o  f o o d  o r  d r i n k ,  e x c e p t  
w a t e r ,  f o r  a t  l e a s t  8  h o u r s  p r i o r  t o  t e s t i n g .  
hI n  t h e  e v e n t  o f  a  p o s i t i v e  u r i n e  l e u k o c y t e  e s t e r a s e  r e s u l t ,  a  r e p e a t  u r i n e  s am p l e  w i l l  b e  c o l l e c t e d and  sh ipp ed  to  th e  c en t r a l  l abo r a to ry .
iA  p o s i t i v e  u r i n e  t e s t  m u s t  b ef o l l ow e d  b y  a  s e r um  p r e g n a n c y  t e s t  f o r  c o n f i rm a t i o n .
jImm u n o g e n i c i t y ,   a n d  PK  s am p l i n g  t o  b e  p e r f o rm e d  a t  t h e  i n d i c a t e d  v i s i t s  a n d  p r i o r  t o  d o s e  a dm i n i s t r a t i o n  i f  t h e  v i s i t  i s  a  d o s i n g  v i s i t .   
S am p l e s  w i l l  b e  t a k e n  i n  t h e  e v e n t  o f  e a r ly  t e rm i n a t i o n .  Imm u n o g e n i c i t y  s am p l e s  a l s o  m a y  b e  c o l l e c t e d  i n  t h e  e v e n t  o f  a  s y s t em i c  a l l e r g i c / h y p e r s e n s i t i v i t y  
r e a c t i o n  ( s e e  S e c t i o n  8 . 4 . 3 ) .   T h e  t im i n g  o f  s am p l e s  w i l l  b e  r e c o r d e d .
kP a t i e n t s  w i l l  r e c e i v e  i n j e c t i o n s  o f  p l a c e b o  o r  LY 2 9 5 1 7 4 2  a f t e r  a l l  o th e r  v i s i t  p r o c e d u r e s  a r e  c om p l e t e d .   F o l l ow i n g  t h e  f i r s t  d o s e  a t  V i s i t  3 ,  p a t i e n t s  w i l l  b e  
o b s e r v e d  f o r  a t  l e a s t3 0  m i n u t e si n  t h e  o f f i c e .
lQ u e s t i o n n a i r e  a dm i n i s t e r e d  b y  c l i n i c i a n  t o  a s s e s s  o t h e r  c h r o n i c  p a i n  c o n d i t i o n s.
mCC I
T h e  C- SSRS  a n d  SHSF  ( a n d  SHFU  w h e n  a p p l i c a b l e )  w i l l  b e  c om p l e t e d  a t  s c h e d u l e d  a n d  u n s c h e d u l e d  o f f i c e  v i s i t s .
I5Q - MC- CGAG  C l in ica l  P ro toco l Page  61
LY2951742Append ix  3 . C l in ica l  Labo ra to ry Tes ts
H em a t o l o g y: C l in i c a l  Ch em i s t r yb:
H em o g l o b i n S e rum  C on c en t r a t i on s  o f :
H em a t o c r i t S o d i um
E ryth ro cy t e  c o u n t  (RBC ) P o t a s s i um
M e a n  c e l l  v o l um e  T o t a l  b i l i r u b i n
M e a n  c e l l  h em o g l o b i n  c o n c e n t r a t i o n  D i r e c t  b i l i r u b i n
L e u k o c y t e s  (WBC ) A l k a l i n e  p h o s p h a t a s e
N e u t r o p h i l s ,  s e gm e n t e d A l a n i n e  am i n o t r a n s f e r a s e  (ALT )
Lympho cyt e s A s p a r t a t e  am i n o t r a n s f e r a s e  (AST )
M o n o c y t e s B l o o d  u r e a  n i t r o g e n  (BUN )
E o s i n o p h i l s C r e a t i n i n e
B a s o p h i l s U ri c  a c id
P l a t e l e t s
H bA1 cC a l c i um
G l u c o s e  ( f a s t i n g)b
A l b um i n
C r e a t i n e  k i n a s e  (CK )
U r in a l y s i s:
S p e c i f i c  g r a v i t y
pH
P r o t e i n
G l u c o s e
K e t o n e s
B l o o d
U ri n e  l e u k o c y t e  e s t e r a s ea
M i c r o s c o p i c  a n a l y s i sa
U ri n e  c u l t u r eaT r i g l y c e r i d e s
T o t a l  c h o l e s t e r o lb
HDLb
I n s u l i n  ( f a s t i n g )b
C -p e p t i d e  ( f a s t i n g )b
O th e r
 
PK  S am p l e  (LY 2 9 5 1 7 4 2  s e r um  c o n c e n t r a t i o n  
d e t e rm i n a t i o n )
Imm u n o g e n i c i t y
U ri n e  D ru g  S c r e e nc
P r e gn an c y  T e s t( f em a l e s  o n l y )c
S e r um  p r e g n a n c yo r FSH
U ri n e  p r e g n a n c y  t e s t( l o c a l )
S t o r ed  S amp l e s
B i om a r k e r  s t o r a g e
RNA
A b b r e v i a t i o n s :   FSH  =  f o l l i c l e- s t im u l a t i n g  h o rm o n e ;  HDL  =  h i g h  d e n s i t y  l i p o p r o t e i n ;
PK  =  p h a rm a c o k i n e t i c ;  CC I
RBC  =  r e d  b l o o dc e l l s ;  RNA  =  r i b o n u c l e i c  a c i d ;  WBC  =  w h i t e  b l o o d  c e l l s .CC I
I5Q-MC-CGAG Clinical Protocol Page 62
LY2951742Clinical Laboratory Tests (footnotes)
aA positive urine leukocyte esterase result will require a follow -up sample with microscopic analysis and possibly 
a urine culture.
bFasting laboratory samples will be collected as shown in the Schedule of Activities (Appendix 2 ). Fasting is 
defined as no food or drink, except water, for at least 8 hours prior to testing.   All other samples may be collected 
on a no nfasting basis.
cMay be repeated during the study at the discretion of the investigator.
I5Q-MC-CGAG Clinical Protocol Page 63
LY2951742Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be requi red in fo llow-up wi th patients in consultat ion with the Lilly , or i ts desi gnee, clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT
CPKAlkaline phosphatase isoenzymes a
Anti -Actin antibody a
Anti -smooth muscle antibody a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
PPDLeo Document ID = ca015047-e81e-494b-ba7f-cc47d68e2898
Approver: 
Approval Date & Time: 23-Sep-2015 19:03:08 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 23-Sep-2015 20:02:22 GMT
Signature meaning: ApprovedPPD